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ABSTRACT

The kappa opioid agonist U-50V488 is known to decrease

the locomotor activity of adult rats.

In contrast, U

50,488 dramatically increases the locomotor activity of
preweanling rats.

Although the mechanisms responsible

for U-50,488's paradoxical effects are uncertain, it is
possible that U-50,488 was increasing locomotor activity
by activating a dopaminergic process.

To assess this

kappa/DA interaction 17- and 80-day-old rats were
treated with the DA antagonist flupenthixol (0.025—0.8

mg/kg, i.p.) prior to an injection of U-50,488 (5.0
mg/kg, S.C.).

Flupenthixol did block U-50,488-induced

activity, but it is possible that this was due to a

general depression in motoric functioning.

Therefore,

the effects of U-50,488, NPA (a direct DA agonist), and

amphetamine (an,indirect DA agonist) were assessed in
17- and 80-day-old rats.

Consistent with previous

studies, U-50,488 increased the locomotor activity of
preweanling rats, while having no effect on the activity
of adult rats.

NPA attenuated U-50,488-induced

locomotor activity, in a dose-dependent manner,

while amphetamine had few effects on U-50,488's activity
enhancing effects.

In these experiments Fos was

assessed in order to determine the specific brain

regions where U-50,488 was working.

Fos

immunohistochemistry indicated that U-50,488 increased

111

Fos expression in several brain regions of the
preweanling rat, including: olfactory tubercles,

habenula, striatum, and preoptic area.

Importantly, NPA

reduced U-50,488-induced Fos induction in the striatum.
In an additional set of experiments, cross-sensitization
was assessed to further examine the kappa/DA interaction

in the preweanling rat.

At 11 days of age, rats were

given an injection of amphetamine or NPA for 5
consecutive days.

Following a two day interval (at 17

days of age), rats received a challenge injection of U
50,488 or the same DA agonist again.

There was no

cross-sensitization between U-50,488 and either of the

DA agonists, suggesting that U-50,488's locomotor
activating effects are not directly mediated through a

dopaminergic mechanism.

Therefore, when taken together

these results suggest that U-50,488's ability to

paradoxically increase the locomotor activity of
preweanling rats is not due to actions on DA neurons.
Rather, the kappa opioid and DA systems appear to have
an antagonistic relationship, as kappa opioid and DA
agonists reciprocally inhibit one another.
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Introduction

Ontogenetic Research Strategy

The ontogenetic research strategy has become an

increasingly popular approach for studying the

neurobiological mechanisms underlying behayior.

Besides

the obvious advantage of enhancing our knowledge of the

developing organismj the Qhtogendtic strategy provides
an additional tool for determining those mechanisms or

systems mediating behavior.

More specifically, as the

animal matures new behaviors emerge as the underlying

neurobiological mechanisms become functional.

Hence,

the ontogenetic process can itself be used as a tool to

pinpoint those receptor or neurotransmitter systems

mediating a particular behavior (see Spear, 1979; Zolman
& McDougall, 1983, for additional reviews).

Recently, a number of different laboratories have
used the ontogenetic research strategy to study the
mediation of behavior by the dopamine and kappa opioid

receptor systems.

In each case, these receptor systems

have been found to exhibit both quantitative and
qualitative changes across development.

Quantitative

changes are the most Common, as drug responsiveness
often shows a monotonic increase according to age.

For

example, dopamine agonists (e.g., apomorphine and
quinpirole) increase the locomotor activity of rats as
young as 4 days of age (Camp & Rudy, 1987; McDougall,

Arnold, & Ncnneman, 1990; Moody & Spear, 1992; Shalaby&
Spear, 1980).

Apomorpliine and quinpirole induce

identical behaviors in older rat pups and adults, but
the potency of these dopamine-acting drugs increases
linearly with age (Moody & Spear, 1992; Shalaby & Spear,

.'i980-)v. . ■

'

of more interest, are those psychopharmacological
effects which exhibit qualitative changes across
development.

For instance, the dopamine mediated

behaviors of preweanling rats are sometimes
characterized by the emergence of new behaviors (e.g,,
grooming), and the occurrence of age-specific behayiors

(e.g., wal1 climbing), which are only found during a

restricted period of developmeht (Mopdy & Spear, 1992;
Shalaby & Spear, 1980).

The kappa opioid system also

shows qualitative ontogenetic differences, as high doses
of U-50,488 (a kappa agonist) decrease the locomotor
activity of adult rats and mice (Hayes, Skihgle, &
Tyers, 1985; Jackson & Cooper, 1985; Leighton, Johnson,
Meecham, Hill, & Hughes, 1987; Ukai & Kameyama, 1985;
Von Voightlander, Lahti, & Ludens, 1983).

In contrast,

high doses of U-50,488 increase the locomotor activity

and wa11-climbing pf preweanling rats (Bolanos, Garmsen,

Glair, McPougall, & Crawford, 1995; Jackson & Kitchen,

1989).
Summarv and Proposal.

'V
When considered together it

M

appears that both the kappa opioid and DA systems induce

behavioral patterns which vary both quantitatively and
qualitatively across development.

Curiously, kappa

opioid agonists and DA agonists have similar behavioral

effects in preweanling rats.

This suggests that in the

these younger animals, kappa neurons may in some way

modulate those DA systems involved with unlearned
activity.

The purpose of this project was to assess the

possible interaction between the DA and kappa opioid
systems in the preweanling and adult rat.

To this end,

17- and 80-day-old rats were treated with a variety of
direct and indirect DA agonists and antagonists, as well
as a kappa opioid agonist.

Fos immunohistochemistry,

was used to identify those pathways activated by the
various drugs.

This study should determine: first, the

behaviors elicited by kappa opioid and DA agonists in

both adult and preweanling rats; second, whether the
kappa and DA systems interact to mediate behavior; and
third, the neuroanatomical regions activated by kappa
and DA agonist treatment.
Dopamine Svstems

Dopamine Receptors.

Dopamine receptors have been

classified into five structurally distinct receptor

subtypes: Di, D2, Da, D4, and Ds (Clark & White, 1987;
Sokoloff, Giros, Martes, Bouthenet, & Schwartz, 1990;

Sunahara et al

1991; Von Tol et al., 1991).

Di and Da

receptors have been differentiated according to
behavioral effects, sensitivity to pharmacological
agents, anatomical locatiori, and effects on second
messenger systems (for a comprehensive review see Clark
& White, 1987).

For example

the Di receptor site

increases adenylyl cyclase g^ctiyity via a Gs protein;
whereas, the Da receptor site exerts an opposing

influence on adenylyl cyelase activity via a Gi protein
(Cooper, Bloom & Roth, 1991; Cunningham & Kelley, 1993).
Behavioral effects of dopamine agonists and

antagonists in adult rats.

DA agpiiists are typically

classified as being either direct or indirect agonists.

Direct DA agonists [e.g., R-propyInorapomorphine (NPA)

and apomorphinel bind to the posf syhaptic recejpfbr and
mimic the endogenous neurotransmitter.

Indirect DA

agonists (e.g. j amphetamine and cocaine) increase the
amount of synaptic DA in a number of different ways/
For example, cocaine blocks the reuptake of DA from the
synapse; whefeas, amphetamine increases DA release into

the synapse (Cooper et al., 1991).

Behavioral responses to DA agonists include, but
are not limited to, locomotion, sniffing, rearing, and
chewing (Arnt, 1987; Clark & White

1987).

Utilization

of selective DA receptor agonists has revealed receptor-

specific behayibral profiles,

bi agonists primarily

enhance grooming^^nd non-steredtyped locomotor activity;
whereas, D2 receptor stimulation enhances Tocorao

activity, rearing, head-down sniffing, and a variety of
oral movements (Arnt, Hyttel, & Perregaard, 1987;
Dall'Olio, Gandolfi, Vaccheri, Roncada, & Montanaro,
1988; Molloy & Waddington, 1985).

The occurrence of

these behaviors is largely determined by dose, as a low

dose of nPa induces locomptor activity and rearing,
while a moderate dose preferentiariy induces head-down
sniffing.

Oral behaviors, like chewing, licking, and

biting, only occur after higher doses of NPA or
apomorphine (Bordi, Carr, & Meller, 1989; McDOugall,
Crawford, & Nonneman, 1993; Mestlin & McDougall, 1993).

Interestingly, although these behaviors are thought to
be primarily Dz-mediated, they are only observed when
both Di and D2 receptors are activated (Barone, Davis,
Braun & Chase, 1986; Longini, Spina & Di Chiara, 1987;

Molloy & Waddington, 1985; Robertson & Robertson, 1986).
Thus, substantial activation of both Di and D2 receptors

is required to produce full expression of highly

stereotyped behaviors like licking and chewing.

Not surprisingly, selective or mixed DA antagonists
can either partially or completely block DA mediated

behavior.

For example, SCH 23390 (a selective Di

receptor antagonist) inhibits grooming induced by the
selective Di agonist SKF 38393; whereas, sulpiride (a

selective Da receptor antagGnist) attenuates NPA-induced
locomotor activity, rearing, and sniffing (Arnt, 1987;
Clark & White, 1987).

Interestingly, Di receptor

blockade also antagonizes the enhanced locomotor

activity, reariiig, and sniffing induced: by; Da^ agonists
(Arnt, 1987; Longoni et al., 1987).

Additionally, the

Di agonist SKF 38393 intensifies or enhances some

behaviors induced by the Da agonist quinpirple
(Mashurano & Waddington, 1989; Robertson & Robertson,
1986).

This DA receptor synergism suggests that either

a tonic level of Di activity is required for the

expression of Da-mediated behaviors ^ or the Da system
modulates the expression of behaviors initiated by the
Di system (Braun & Chase, 1986; McDougal1 et al., 1990;

Molloy & Waddington, 1985; Robertson & Robertson, 1986).
The ability of DA antagonists to attenuate or block

the effects of DA agonists has been discussed; however,

DA antagonists are also capable of eliciting their own
behavipral effects.
catalepsy in rats.

DA receptor antagonists produce
For example, SCH 23390 and YM-09151

(selective Di and D2 antagonists, respectively) produce
a dose-dependant increase in catalepsy in adult rats

(Christensen, Arnt, Hyttel, Larsen, & Svendsen, 19841
Terai, Usuda, Kuroiwa, Noshiro, & Maneno, 1983;
Wanibuchi & Usuda, 1990).

Furthermore, antagonists that

block both Di and D2 receptors (e.g., haloperidol and

flupenthixol) most potently induce catalepsy (Verma &
Kulkarnij 1992; Wanibuchi & Usuda, 1990).
Behavioral effects of dopamine agonists and

antagonists in preweanling rats.

In general,

preweanling rats exhibit adult-like behavior patterns
wheri treated with direct and indirect DA agonists.

Like

adult rats, preweanling rats display increased rearing
and locomotor activity after acute treatment with the
indirect DA agonists amphetamine and cocaine (Barrett,

Gaza, spear, &•Spear, 1982; Campbell, Lytle, & Fibiger,

1969; Shalaby & Spear

1980).

Similarly, nonselective

direct DA agonists (e.g., apomorphine and NPA) enhance
locomotor activity and sniffing in both the preweanling

and adult rat (Arnt, 1987; Mestlin & McDougall, 1993;
Shalaby & Spear, 1980).

Preweanling rats, in general,

also display adult-like behavioral responses after
treatment with selective DA agonists.

For example, SKF

38393 (a selective Di agonist) increases locomotor

activity in both 3- and 21-day-old rats, with increased
sniffing evident in slightly older rats.

Although the

complete Da agonist behavioral profile (i.e., locomotor

activity, rearing, and sniffing) is not observed until
at least 21 days of age, quinpirole (a selective Da

agonist) enhances locomotor activity at all ages (Eilam
& Szechtman, 1989; Moody & Spear^ 1992; Walters &
Howard, 1990).

Occasionally, DA agonists will produce

some age-dependant behavioral effects, however they are
often due to the maturation of motoric ability and not

because of qualitative changes in dopaminergic
functioning.

As with adult rats, the Di and D2 receptofs of
preweanling rats interact when mediating some behaviors,
however the specific behaviors showing synergism often
vary between preweanling and adult rats.

For example,

co-administration of Di and D2 agonists (i.e., SKF 38393

and quinpirole) in 10-day-old rats induces a significant
decrease in mouthing; whereas, 21-day-old rats show
stereotyped licking after combined agonist treatment

(Moody & Spear, 1992).

Similarly, 3- and 10-day-old

rats exhibit synergistic increases in DA agonist-induced
wall climbing and locomotor activity, while they fail to
show stereotyped oral movements.

Therefore, the Di and

D2 receptors of preweanling rats appear to interact when
mediating some behaviors, however, the specific
behaviors showing D1/D2 synergism vary according to age.

Studies using DA antagonists also suggest that the
DA receptor systems of young and adult rats are

generally similar.

For example, the quinpirole-induced

locomotor activity of preweanling rats is antagonized by
either SCH 23390 or sulpiride (Di and D2 antagonists,
respectively), while SKF 38393-induced grooming is
blocked by SCH 23390 (McDougall et al., 1990).

In

addition, selective Di and D2 antagonists induce adult
like catalepsy in the preweanling rat, with the most
intense catalepsy being induced by joint D1/D2

antagonist treatment (Baez, Burt, Granneman, & Shanklin,
1979; Fitzgerald & Hannigan, 1989).

To summarize, preweanling and adult rats display
similar patterns of behavioral responding after DA
agonist and antagonist treatment.

In general, DA

receptor activation elicits locomotor activity and
rearing, with more stereotyped behayiors, such as

sniffing, chewing, and biting, occurring when higher
doses of a DA agonist are used.

Furthermpre, DA

antagonists produce a dose-dependant decline in DA

mediated behaviors, with catalepsy occurring at higher
doses (Arnt, 1987; Baez et al., 1979; Clark & White,
1987).
Opiate Systems

Qpioid Receptors.

Opioid receptors have been

classified into three structurally distinct receptor
subtypes: mu, delta, and kappa (Lord, Waterfield,
Hughes, & Kosterlitz, 1977; Martin, Fades, Thompson,
Huppler, & Gilbert, 1976).

Mu and delta receptors have

been differentiated according to pharmacological action

(Gilbert & Martin, 1976; Martin et al., 1976; Wollemann,

Benyhe, & Simon, 1993).

For example, receptor binding

studies have revealed that morphine possesses high

affinity for mu feceptors; whereas^ delta receptors are
activated by enkfephalins (Brady &Holtzman, 1981;
Wolleraann et al. i 1993).

Pharmacological Studies have

shown that kappaireceptors are different from mu and
delta receptors, i and they have been divided into three

distinct subclasses: kappai, kappa2, and kappas
receptors (Wollemannet al., 1993).

More specifically,

kappai Sites havfe a high affinity for benzeneacetaminde

compounds (like |U^50,488); whereas, kappaa and kappas
sites display little affinity for U-50,488 (Wollemann et
al., 1993).

The various opiate receptor subtypes can also be

distinguished by; their behavioral effects.

It is known

that mu agonists (e.g., DAGO and morphine) are involved

in pain modulation and activate reward processes;
whereas, kappa agonists (e.jg., tifluadom, bermazocine,

and U-50,488) reduce the spontaneous behavior of rats,
and appear to have aversive effects when tested in the
self-administration paradigm (Di Chiara & Imperato,
1988; Mucha & Herz, 1985; Yaksh, 1986).

Evidence

suggests that opiate receptor activation plays a largely
modulatory role in behavior.

In general, opiate

receptor agonists inhibit the release of other
neurotransmitters.

Mu and delta agonists inhibit

release of coftical noradrenaline and striatal

acetylcholine; whereas, kappa receptor activation
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inhibits dopamine release in the striatum and cortex

(Wollemann et al., 1993).
Behavioral effects of mu and delta opioid agonists
and antagonists in adult and preweanling rats.

In

general, mu receptor activation modulates pain and
reward system functioning; however, the unlearned motor
behaviors are affected as well.

In adult rats,

increased lopomotor activity occurs after low doses of
morphine (1-2 mg/kg); whereas, higher doses (5-20 mg/kg)
induce behavioral depression, including reduced
locomotor activity and catalepsy (Brady & Holtzman,

1981; Fog, 1972).

In contrast, morphine and DAGO (mu

agonists) have only cataleptic and sedative effects in

the preweanling rat (Bolanos et al., 1995; Caza & Spear,
1982; Jackson & Kitchen, 1989; Katz, 1984).
Behavioral responses to delta agonists also vary
across ontogeny.

Treatment with low doses of DPDPE (a

delta agonist) increases the locomotor activity,

rearing, and sniffing of adult rats; whereas, higher
doses ipduce behavioral deprpssion (Cowan, Ranee, &
Blackburn, 1986; Cowan, Zhu, & Porreca, 1985).

In

contrast, DPDPE does not affect the behaviors of

preweanling rats (Jackson & Kitchen, 1989).

In summary,

agonists at the mu and delta opiate receptor have

pronounced age-dependent behavioral actions in
preweanling and adult rats.
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Behavioral effects of kappa OTaioid agonists and

antagonists in adult rats.

Kappa agonists induce

conditioned place aversions and taste aversions in adult

animals (Bechara & Van der Kooy, 1987; Mucha & Herz,
1985),

The aversive properties of U-50,488 are mediated

at both the peripheral and central level, with the
central- effects possibly resulting from decreased DA

release within the nucleus accumbens (Bals-Kubic, Herz,

& Shippenberg, 1989; Bechara & Van der Kooy, 1987; Di
Chiara & Imperato, 1988).

Kappa receptor activation

alsp affects Unlearned behaviors,

In both rats and

mice, decreased locomotor activity follows treatment
with U-50,488, tifluadom, and bermazocine (Castellano &

Pavone, 1987; Crawford, McDougaTl, Bolanos, Hall, &

Berger, 1995; Hi Chiara & impeirato, 1988; Friyette &
Terrian, 1995; Von Voightlander et al., 1983) ^
Interestingly, kappa agonists elicit a dose-dependant

behavioral depression similar to that mediated by DA

antagonists.

For example, U-50,488 (5 or 10 mg/kg,

s.c.) attenuates the locomotor activity of adult rats;

whereas, catalepsy follows higher doses of the kappa
agonist (Jackson & Cooper, 1985; Ukai & Kameyama, 1985;

Von Voightlander et al., 1983).
Further evidence for the role of the kappa receptor

in behavior is provided by studies using the selective
kappa antagonists binaltorphimine and nor
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binaltorphimine (nor-BNI).

Although these compounds

have only recently been developed, it has been shown
that U-50,488-induced catalepsy and antinociception are
blocked by hor-BNI {Jones & Holtzman, 1992).

The later

results are important, because they clearly indicate
that U-50,488 is affecting behavior by Acting at the

kappa receptor.

In suminary, the kappa opioid systems

ability to decrease DA release inhibits unlearned
activity, and the mediation of conditioned place
aversion and taste aversion in adult rats (Bechara & Van

der Kooy, 1987; Carr, Bak, Simon, & Portoghese, 1989;
Crawford et al., 1995).
Behavioral effects of kappa opioid agonists and
antagonists in preweanling rats.

In direct contrast to

adults, the kappa agonist U-50,488 elicits a dosedependent increase in the locomotor activity of the

preweanling rat (Bolanos et al., 1995; Jackson &
Kitchen, 1989; Kehoe & Boylan, 1994).

Furthermore,

kappa agonists, like DA agonists, elicit age- and dose

dependant behavioral responding in the fetal and
preweanling rut.

For example, U-50,488 promotes dCse

dependant increases in the activity of the fetal rat by
as early as day 21 of gestation (Smotherman, Moody,
Spear, & Robinson, 1993).

In 5- and 10-day-old rats U

50,488 (0.1 and 1.0 mg/kg) preferentially enhances
locomotor activity and wall-climbing; whereas, wal1
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climbing predominates in the 20-day-C)ld {Jackson &
Kitchen, 1989).

Dbse is an important constraint on U

50,488's effects, as 10 mg/kg U-^50,488 initially sedates

the 20-day-old rat, with wall-climibing and locomotor
activity emerging as the drug wears off (Birch & Hayes,
1987; Jackson & Kitchen, 1989).

The paradoxical effects of the kappa agonists in

the preweanling rat, however, appear to be confined to
increased locomotor activity.

Similar to adult rats,

kappa opiates produce an analgesic effdct in pireweanling
rats (Barr, 1992; Barr, Paredes, Erickson, & Zukinj
1986).

Furthermore, 3- and 7-day-old rats given U

50,488 display,Cbnditi

piace aversions like aduIt

rats (Barr, Wang, & Garden, 1994).

These findings

indicate tha:t the analgesic and aversive properties of
the kappa agonists are similar in adult and preweanling

rats.

Moreover, these resnlts suggest that U-50,488's

locomotor activating effects in the preweanling rat are
not caused by the aversive effects of this drug (Barr et
al., 1994; Garden, Barr, & Hofer, 1991).

The role of kappa receptors in mediating the
behavioral responses of preweanling rats was confirmed
using nor-BNI (a kappa antagonist).

For example, U-

50,488-induced analgesia and locomotor activity are

blocked by nor-BNI (Jackson & Kitchen, 1989; Kehoe &
BoyIan, 1994).

In contrast, selective mu or delta

14

antagonists (e.g., M8008 and ICI 174,864, respectively)
do not affect the activity enhancing actions of U-50,488

in the preweanling rat (Birch & Hayes, 1987).

Interestingly, treatment with SCH 23390 (a selective Di

receptor antagonist) fails to inhibit the fetal motor
behavior produced by U-50,488 (Smotherman et al., 1993).
However, the kappa antagonist nor-BNI effectively blocks
both U-50,488- and SKF 38393-induced motor activity in

the fetal rat (Smotherman et al., 1993).

This suggests

that fetal motor behaviors are initially mediated by the
kappa receptor, with the DA system only modulating kappa
functioning (Robinson, Moody, Spear, & Smotherman, 1993;
Smotherman et al., 1993).

This DA-to-opioid interaction

differs from the typical opioid-to-DA pattern reported

in adult studies (DeVries, Hogenboom, Mulder, &
Schoffelmeer, 1990; Mulder, Wardeh, Hogenboom, &
Frankhuyzen, 1984; Schoffelmeer et al., 1988).

This may

reflect differences in experimental methodology, or may
indicate ontogenetic changes in the relationship between

the kappa opioid and DA systems (Smotherman et al.,
1993).

If the latter is correct, developmental

differences could be mediated by changes in the
distribution of kappa opioid receptors within the CNS

(Smotherman et al., 1993).
In summary, although the behavioral responses
elicited by kappa opioid agonists in adult rats have
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been well documented, there has been relatively little

examination of the behavioral effects of these drugs in

the preweanling rat.

Even so, kappa agonists do appear

to produce pronounced age-dependant effects in the
preweanling and adult rat.

Kappa agonists inhibit

behavioral responding in the adult; whereas, these same,
drugs enhance behavioral activity, including locomotion
and wall climbing, in the preweanling rat (Bolanos et
al., 1995; Jackson & Kitchen, 1989; Locke & Holtzman,
1986; Smotherman et al., 1993).

Importantly, the

pattern of these behavioral responses provides further

evidence that the kappa opiate and DA systems interact
to mediate behavior.

Dopamine Pathways

The dopaminergic system is highly organized
topographically.

On the basis of their efferent

projections, dopaminergic cell groups have been broadly
classified into two groups: (1) the mesolimbic

mesocortical pathway and (2) the nigrostriatal pathway
(Cooper et al., 1991; Role & Kelly, 1991).
Mesolimbic-mesocortical pathway.

DA fiber

projections making up the mesolimbic-mesocortical
pathway have their cell bodies in the ventral tegmental

area (VTA).

The cells of the mesolimbic component of

this pathway project from the VTA to the limbic system,
primarily the nucleus accumbens (Cooper et al., 1991;
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Koob, 1992)/

Recently) an p

model has been

prpiposed to explain the interactions between the opiate
and DA systerns (see Figure 1) (Di Chiara & North, 1992;
Spanagel, Herz, & Shippenberg, 1992).

Two opposing

opipid systems, located in different parts of the
mesolimbic system, modulate DA neurons projecting to th

nacleus aCCumbens.

Mu receptors located on GABA

inhibitbry heurOns in the VTA disinhibit DA neurons

projecting to the nucleus accumbens.

Thus, the mu-

induced reduction of GABA^fflediated Inhibition
facilitates DA release in the nucleus accumbens.

in

contrast, kappa receptors, located on DA terfflinals in

the nucieus acCumbens, inhibit DA release.

The opposing

actions of the two opioid systems assist in the

maintenance Of basal DA rbiease in the nucleus accumbens
(Di Chiara & North, 1992; Spanagelet al., 1992).

This

model, and the evidence supporting it, suggests that the
kappa opioid system plays an ifflportant role in

mpdulatirtg DA input, particularly in the nucleus
. accumbens-..

Behavioral evidence generally supports this

kappa/DA model.

For example,fflicroinjections of d-

amphetamine into the nucleus accu®®hens produces

locomotor activity in adult rats (Colle & Wise, 1991).
Further, injections of NPA into the nucleus accumbens

results in a dose-dependant increase in oral behaviors
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and sniffing (Bordi et al., 1989).

Although

microinjection studies using kappa agonists have not yet

ijeen reported, systdinic treatment with U-50,488
pfesumahly depresses the locomotor activity of ddult
rats by decreasing DA release in the nucleus accumbens

(Crawford et al., 1995; Di Chiara & Imperato, 1988).
Consistent with this, kappa agonists reduce, and kappa
antagonists increase, DA release in the aCcumbens (Di
Chiara & Imperato, 1988; Spanagel et al., 1992).
Nigrostriatal pathwav.

The nigrostriatal pathway

originates in the substantia nigra and projects

primarily to the striatum, composed of the putamen and
caudate nucleus (Nolte, 1981).

The substantia nigra,

which lies in the midbrain, has two zones: the pars

reticulata and the pars compacta.

Receptor binding

studies indicate that large amounts of opiate receptors

(mu and kappa) are present in the pars compacta, with
low levels present in the pars reticulata (Matsumoto,

Brinsfield, Patrick, & Walker, 1988; Merchenthaler,
Maderdrut, Altschuler, & Petrusz, 1986).

Evidence

suggests that kappa opioid agonists have dual opposing

effects on activity:

a motor activating effect mediated

by nondopaminergic pars reticulata cells and a motor

inhibitory effect mediated through the pars compacta DA
cells (Matsumoto et al., 1988).

For example, treatment

v/ith U-50,488 reduces locomotor activity by decreasing
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the firing rhte of dopamine cells in the shhstantia

nigria fWalker j /fhoiHpsoh, Frascella, & Frederick, 1987) C :
and by decreasing the release of dopamine in the

striatuiB (iHJperato & Di Chiara, 1985).
Micrbiajections of DA agonists directly into the

striatuin produce a wide ranga of behavioral respohses•
Episodes Of DA-m^^

loeomotor activity, rearing, and

grooming follow iRjections of low doses of NPA into the

siriatam (Bordi et al., 1989).

Furthermore, injections

Of NPA of apomorphine into the striatum also enhances
sterOOtyped: sniffing and oral behaviors.

At doses from

5.0^20 JUg a linear increase in both behaviors is

evident; whereas, at higher doses (40 >tg> the increased
receptor occupancy results in stereotyped behavior,

comprised of enhanced oral behaviors accompanied by a

decrease in sniffing {Bprdi et al., 1989; Scheel-Kruger
& Afnt, 1985).

Furthermore, microinjections of U-50,488

into the Substantia nigra pars reticuiata elicits long

dufation rotational behavior (Matsumoto et a1., 1988).

These findings suggest that kappa opiate receptors
1ocated in the nigrostr1atal pathway are invo1ved in the
regulation of DA-mediated skjtor function.

This evidence

indicates that opiate receptor agonista elicit
behavioral respdnses by activatihg both the mesolimbic

mesocortical and nigrostriatal pathways (Matsumoto et
al., 1988).

.,

/y
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In suHJmary j DA pathw^

are both topographieaily

and bebayiorally dissbciable.
mesoeortieal pathway prpjeets

The fflesoliffibiG
the ventral tegmental

area to linibio and CGrtical regiGns and appears to be
neeessary for a nuHiber of DA-mediated behayiors.

The

nigtostriatal pathway projects froia thb snbstantia higra
to several striatal regions and is most eritieally
involved in mediating stereGtyped behaviGr, Evidence

shows that kappa opiate receptors are present and active

in both pathways, affecting behavior by fflodulating DA
"' .•rel.ease'i, ,

Fos Immiinohistochemistrv.
is a new techniqne w^^

Fos immunohistochemistry
ideally suited for

determining the pfecise location of heuronal activation.

Various DA-^acting drugs elieit the trahsient expression

of Fos, the p^

the early response gene e-/bs

{DragunGw, RGd>ertsGn, Fauil, Robertson, & Jansen, 199G;
Graybiel, Moratalla, & Robertson, i99D).

Therefore, Fes

expression reflects neuronal activity in the CNS

(Miller, 1990; Sagar, Sharp, & Curran, 1988).

Following

treatment with amphetamine, enhanced locomotor activit^^^^^^^
is accompanied by extensive c-fos induction in the

medial two-thirds of the striatum, as well as the

nucleus accumbens, olfactory tubercles, and a variety of
other brain regions (Bullitt, 1990; Graybiel et al.,
1990; Sharp, Gonazales, Sharp, & Sagar, 1989; Snyder
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Keller, 1991; Torres & Rivier, 1994).

Likewise, cocaine

produces large increases in striatal c-fos expression,
which is potently blocked by the selective Di receptor

antagonist SCH 23390 (Carney, Tolliver, Carney, & Kindy^,^^^^
1991; Dragunow et al., 1990).

Utilizat

o

immunohistochemiStry fG1Ipwin

administration of thb

kappa agonist U-50,488 should elucidate the specific
brain areas involved in the opioid activation of
behavior.
Kappa/Dopamine Interactions

Behavioral and pharmacological evidence suggests

that kappa raceptors may affect behavior by modulating
the functioning of DA neurons.

Consistent with this,

Crawford et al. (1995) have shown that the kappa opioid
agonist U-50,488 antagonizes cocaine-induced locomotor

activity in adult rats.

This indicates that kappa

neurons moduiatP those DA systems involved in unlearned
activity.

cocaine-induced Fos

imraunoreactivity in the adult rat is blocked by U-50,488
pretreatment, further indicating that the DA and kappa
opioid systems interact (Crawford et al., 1995).
In summary, behavioral studies indicate that there

is a substantial ontogenetic change in the way that the
kappa and DA systems iat^^^

to mediate behavior.

specifically, U-50,488

More

the loeomptor activity

of prewbanling rats, while decreasing the locomotor
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activity of adult rats (Bolanos et al., 1995; Jackson &

Kitchen, 1989; Kehoe & Boylan, 1994; Sniotheraian et al.,
1993).

In adults, the U-50,488-induced decrease in

locoBiotor activity is presumably due to the modulation

of DA functioning in the substantia nigra and/or nucleus
accumbens; however, the neurobiological mechanisms

underlying U-50,488's behavioral activating effects in

preweanling rats is entirely unknown.

Interestingly,

the locomotor activating effects of kappa and DA
agonists are similar in the preweanling rat, suggesting
that kappa neurons may, in some way, modulate those DA

systems involved with unlearned activity.

The present

study further examined this kappa/DA interaction in

order to elucidate the mechanisms involved in the kappamediated behaviors of preweanling rats.
This project assessed the possible interaction

between the DA and kappa opioid systems in the
preweanling rat.

proposed:

A total of six hypotheses were

(1) I proposed that the kappa agonist U

50,488 would decrease locomotor activity in the adult

rat: a result that has been reported previously

(Crawford et al., 1995); (2) As previously shown, U
50,488 was expected to increase the locomotor activity

of the preweanling rat (Bolanos et al., 1995; Jackson &
Kitchen, 1989; Kehoe & Boylan, 1994); (3) U-50,488 was
expected to potentiate amphetamine- and NPA-induced
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locomotor activity and sniffing.

This w

that U-50,488 and the DA agonists are inodhlating
behavior by affecting the same nebroahatofiiical pathways;
(4) Flupenthixol (a nonSelective DA receptor antagonist)
was predicted to redpce U-5G,488-mediated iocQmoto^^
activity.

This would indicate that the behaviors

elicited by this agonist are ultimately DA mediated; (5)
Amphetamine and NPA would induce regional expressibn of

FOS immunoreactiVity in the preweanling rat: an

observation pbserved in adult rats, but hot tested in

preweaniing rats (hdbbrtspn, Petersoni Murphy, &
Robertson, 1989; Snyder-Keller, 1991); (6) U-50,4S8-,
amphetamine-, and NPA-mediated Fos immunoreactivity was
predicted to occur in the same brain regions.

This

would pinpoint those brain areas involved in unlearned
activity; moreoyer, it would indicate that the kappa and
DA agonists are affecting the same pathways.
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FIGURE CAPTION

Figure 1. Proposed model for the modulation of DA
neurons by opposing tonically active endogenous opioid
systems. In the ventral tegmental area a tonically
active mu opioid system stimulates the DA neurons via
disinhibition of the GABA-containing interneuron. In
the nucleus accumbens a tonically inhibitory kappa
opioid system suppresses the release of DA by AlO
neurons. The action of both opioid systems is necessary
for the maintenance of basal DA release.

24

53-EP
./A^tonus
tonus.

Mesolimbic

GABA

pathway

interneuron

VTA

NA

25

General Method
Subi ects . ■

Subjects were 248 male and 248 female Sprague-

Dawiey rats (Harlan).

Lltters were culled to 8 to 10

rat pups at three days of age.

eithef 17 or 80 days of age.

Rats were tested when

The 17-day-olds were

housed with the dam prior to behavioral testing.

The

80-day-old rats were individually housed until the test
day.

Assignment of male and fema1e rat pups was

counterbalanced, with no more than one rat from each

litter being placed into a particular group.

The colony

room was maintained at 23-25oc and kept under a

14:10/L:D cycle.

Behavioral testing was conducted

during the light phase of the cycle.
Apparatus

Behavioral testing was done in grey p1ywood

chambers (30 x 30 x 42 cm), with floods divided by lines
into four equdl quadrants.
Evaluation of behavioral testing

A single line-cross was scored when a rat's front

two paws completely crossed one of the lines dividing

the floor of the testing chamber.

Line-crossing was

measured continuously across the testihg session,

whereas the Pecurrence of stereotyped (head-down)

sniffing was assessed every 20 s using a time sampling
procedure.
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Drugs

The drugs used were d-amphetamine sulfate

Chemieals, St. Louis, Mo.), i?-propyinorapomorphine
(NPA)i

flupenthixol (Research

Biocheiriicais, Natick, Mass).

All drugs were mixed in

saline at a volume of 5 ml/kg.

U-50,488 was injected

subcutaneously (s.c.), whereas all other drugs were
injected intraperitoneally (i.p;).
Statistics

Analyses of variance (ANOVAs) were used for the
statistical analysis of both the behavioral and

immunohistochemistry data.

For the locomotor activity

data repeated measures ANOVAs were performed across six
10-min time blocks; whereas, the sniffing data was
analyzed across two 30-min time blocks for the initial

four experiments.

For the remaining experiments,

sniffing data was analyzed using repeated measures
ANOVAs across six 10-min time blocks.

Data from the Fos immunohistochemistry experiment
were analyzed using two-way ANOVAs (for each brain

region).

When appropriate, Tukey tests (P<0.05) were

used for making post hoc comparisons.

U-50,488 has been

shown to increase the locomotor activity of the

preweanling rat (Bolanos et al., 1995).

Therefore, it

was predicted that U-50,488 would enhance Fos expression
in the 17-day-old rat, but not the adult rat.
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To

analyze the effects of y-50,488 on Fos expression ttests (P<0.05) were used to compare U-50,488- and
saline-treated rats.

■ ' .■ ■Experiment--.''la' ' 

The Behaviorai Effects of U-50,488,
a Kappa Opioid Agbnisty in T7--Day-Old Rats
Method

j

Sublects,

.

Thirty-two male arid female 17-day-old

Sprague-Dawley albino rats (Harlan) werb used.

Procedure.

Four groups of 17-day-old rats (n= 8)

received an acute injection of U-50,488 (0, 2, 5, or 10
mg/kg) immediately prior to the behavioral testing
session.

Line-crosses and stereotyped (head-down)

sniffing were assessed during a 60-min testing session
by an observer blind to treatment conditions.
Results

■ ■ ;;

Line-crosses.

Overall, 17-day-old rats treated

with U-50,488 (2.0, 5.0, 10.0 mg/kg) had significantly
more line-crosses than saline controls (see Figure 2)

[condi tion main ef fect ,v J^( 3 , 2
Tukey tests, P<0.05].

P<0 .001; and

The total number of 1ine-crosses

decreased across testing [time main effect,

F{ 5,140)=8.68, P<0.001; and Tukey tests, P<0.05],
During the initial testirig block, rats injected with

10.0 mg/kg U-50,488 had significantly more line-crosses
than rats given 2.0 mg/kg or 5.0 mg/kg U-50,488
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[Condition X Time interaction, F(15,140)=3.82, P <0.001;
and Tukey tests, P <0.05].

However, for the remainder

of testing there were no significant differences between
U-50,488-treated rats.

Stereotyped sniffing.

There were no significant

differences between 17-day-old rats injected with either
U-50,488 or saline (see Table 1).
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FIGURE CAPTION

Figure 2.

Mean number of line-crosses during the 60-min

behavioral testing session.

The 17-day-old rats (n = 8)

were injected with U-50,488 (2.0, 5.0, or 10.0 mg/kg,

s.c.) or saline immediately prior to behavioral testing.
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Table 1.

Mean stereotyped sniffing counts (+SEM)' of 17

day-old rats given U-50,488 (0.0--10.0 mg/kg).
Behavioral testing occurred immediately after U-50,488
treatment and was recorded for 60 min (divided into two
30-min testing periods).

Stereotyped Sniffing Counts

U-50,488

First 30 Min

Second 30 Min

0.0

mg/kg

0.75

+

0.49

0.25

+

0.25

2.0

mg/kg

4.63

+

0.94

2.25

+

0.79

5.0

mg/kg

6.25

+

5.97

2.63

j-

2.63

10.0

mg/kg

0.88

0.49

1 .50

+

0.59
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Experiment lb

The Behavioral Effects of Amphetamine,
an Indirect DA Agonist, in 17-Day-Old Rats
Method

Subjects.

Thirty-two male and female 17-day-old

Sprague-Dawley albino rats (Harlan) were used.
Procedure.

Four groups of 17-day-old rats (n = 8)

received an acute injection of amphetamine (0, 1, 2.5,
or 5 mg/kg) immediately prior to behavioral testing.
Line-crosses and stereotyped (head-down) sniffing were
assessed during a 60-min testing session by an observer
blind to treatment conditions.
Results

Line-crosses.

Overall, rats given amphetamine had

significantly more line-crosses than rats receiving

saline (see Figure 3) [condition main effect,
F(3,28)=3.90, P<0.05; and Tukey tests, P<0.05].

The

total number of line-crosses decreased across testing
[time main effect, F(5,140)=19.01, F<0.001; and Tukey
tests, P<0.05].

Across the initial two testing blocks

rats receiving amphetamine had significantly more line-

crosses than the saline controls (see Figure 3)
[Condition X Time interaction, P(15,140)=2.17, P<0.01;
and Tukey tests, P<0.05].

However, only rats receiving

1.0 mg/kg amphetamine had significantly more linecrosses than saline controls on each of the testing
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blocks [Tukey tests, P<0.05].

Stereotyped sniffing.

Overall, rats given 5.0

mg/kg amphetamine had significantly more stereotyped

sniffing counts than saline-treated rats {see Table 2)
[condition effeet, F(3,28)=4.15, P<0.05; and Tukey

tests, F<0.05].

Rats receiving 1.0 and 2.5 mg/kg

amphetamine did not differ from the saline controls.
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FIGURE CAPTION

Figure 3.

Mean number of line-crosses during the 60-min

behavioral testing session.

The 17-day-old rats (n = 8)

were injected with amphetamine (1.0, 2.5, or 5.0 mg/kg,
i.p.) or saline immediately prior to behavioral testing.
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Table 2. Mean stereotyped sniffing cpuiits (+SEM) of 17
day-old rats given amphetamine (0.0--5.0 nig/kg).
Behavioral testing occtirred iniinediately after treatinent
and was recorded for 60 min {divided into two 30-min

.testing ■,peripds)V "■
Stereotyped Sniffing Counts
Amphetamine

First

30 Min

Seebnd 30 Miri

0.0 mg/kg

0.50 +0,33

0.50 ± 0.38

1.0 P

4.00+2.67

2;25 +1.14:

2.5 mg/kg

5.0 ing/kg

1.50 ± 1.05
12.00 + 4.74A

3.25 + 1.194

ASignificaht cdndition main effect indicating that
amphetamine-treated rats v/ere sigriifican11y different

from the saline-treated rats, P<0.05.
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Experiment Ic

The Behavioral Effects of NPA,

a Direct DA Agonist, in 17-Day-Old Rats
Method

Subiects.

Thirty-two male and female 17-day-old

Sprague-Dawley albino rats (Harlan) were used.

Procedure.

Four groups of 17-day-old rats (n = 8)

received an acute injection of NPA (0, 0.1, 0.3, or 1.0

mg/kg) immediately prior to behavioral testing.

Line-

crosses and stereotyped (head-down) sniffing were
assessed during a 60-min testing session by an observer
blind to treatment conditions.
Results

Line-crosses.

Overall, all of the NPA-treated

groups had significantly more line-crosses than the

saline group (see Figure 4) [condition main effect,
F(3,28)=16.74, P<0.001; and Tukey tests, P<0.05].

The

total number of line-crosses decreased across testing
[time main effect, P(5,140)=32.96, P<0.001; and Tukey
tests, P<0.05].

Rats given 0.3 and 1.0 mg/kg NPA had

significantly more line-crosses than the saline controls

on all of the testing blocks [Condition X Time

interaction, P(15,140)=3.25, P<0.001; and Tukey tests,
P<0.05].

The rats receiving 0.1 mg/kg NPA only differed

from the saline controls on the first two testing blocks
[Tukey tests, P<0.05].
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stereotyped sniffing.

Overall, 17-day-old rats

injected with NPA had significantly more stereotyped
sniffing counts than saline controls (see Table 3)
[condition main effect, F(3,28)=16.74, i'<0.001; and
Tukey tests, P<0.05].

The differences between the NPA

and saline groups were apparent on both test periods

[Condition X Time interaction, F(3,28)=3.41, P<0.05; and
Tukey tests, P<0.05].

During the second testing period,

rats given 0.3 mg/kg NPA had significantly more sniffing
counts than all other groups [Tukey tests, P<0.05].
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FIGURE CAPTION

Figure 4.

Mean number of line-crosses during the 60-min

behavioral testing session.

The l7-day-old rats {n = 8)

were injected with NPA {G.l, 0.3, or 1.0 mg/kg, i.p.) or
saline immediately prior to behavioral testing.
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Table 3. Mean stereotyped sniffing counts (+SEM) of 17
day-old rats given NPA (0.0--1.0 mg/kg). Behavioral
testing occurred immediately after NPA treatment and was
recorded for 60 min (divided into two 30-min testing
periods).

stereotyped Sniffing Counts

NPA

First 30 Min

0 i 0 mg/kg

1.12

0.44

Second 30 Min

0.00

0.00

0.1 mg/kg

32.75 +2.06^

24.13 + 2.83^

0.3 mg/kg

38.13 + 6.18^

44.75+ 5.63ab

1.0 mg/kg

38.50 + 5.45®

23.75 ±5.03®

®Significant Condition X Time interaction indicating
that rats given NPA had significantly more

stereotyped sniffing counts than saline-treated rats
during both testing periods, P<0.05.

^Significant Condition X Time interaction indicating
that the 0.3 mg/kg NPA group was significantly
different from all other groups during the final 30
min testing period, P<0,05.
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Experiment Id
The Behavioral Effects of U-50,488,

a Kappa Opioid Agonist, in 80-Day-Old Rats
Method

Subjects.

Thirty-two male and female 80-day-old

Sprague-Dawley albino rats (Harlan) were used.
Procedure.

Four groups of 80-day-old rats {n = 8)

received an acute injection of U-50,488 (0, 2, 5, or 10

mg/kg) immediately prior to behavioral testing.

Line-

crosses and stereotyped (head-down) sniffing were

assessed during a 60-min testing session by an observer
blind to treatment conditions.
Results

Line-crosses.

Overall, rats given 2.0 mg/kg U

50,488 had significantly more line-crosses than rats
receiving saline (see Figure 5) [conditiCn main effect,

F(3,28)=3.63, P<0.05; and Tukey tests, P<0.05].

There

was a rapid decline in the total number of line-crosses
across testing [time main effect, P(5,140)=107.18,

P<0.001; and Tukey tests, P<0.051.

For example, from

the first to second testing block, there was a

significant decrease in line-crosses of rats given 10.0
mg/kg U-50,488 [Condition X Time interaction,

P(15,140)=3.26, P<0.001* and Tukey tests, iP<0.05].

Rats

given 2.0 mg/kg U-50,488 had significantly more linecrosses than saline- and 10 mg/kg U-50,488-treated rats

43

during the second testing block [Tukey tests, i'<0.05].
There were no significant differences betv/een U-50,488

and saline-treated rats during the fourth and fifth

testing blocks.

During the final testing block, rats

given 10.0 mg/kg U-50,488 had significantly more linecrosses than saline-treated rats [Tukey tests, P<0.05].
Stereotyped sniffing.

Overall, the total number of

sniffs declined from the first to the second testing

period (see Table 4) [time main effect, F(1,28)=75.81,
i'<0.001].

There were no significant differences in

sniffing counts between saline- or U-50,488-treated
rats.
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FIGURE CAPTION

Figure 5.

Mean number of line-crosses during the dO-min

behavioral testing session.

The 80-day-old rats {n = 8)

were injected with U-50,488 (2.0, 5.0, or 10.0 mg/kg,

s.c.) or saline immediately prior to behavioral testing.
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Table 4. Mean stereotyped sniffing counts (+SEM) of 80
day-old rats given U-50,488 (0.0--10.0 mg/kg).
Behavioral testing occurred immediately after U-50,488
treatriient and was recorded for 60 min (divided into two
30-min testing periods).

Stereotyped Sniffing Counts

First 30 Min

Second 30 Min

mg/kg

2.75 + 0.86

2.25 + 0.61A

2.0

mg/kg

4.25 ± 0.82

4.25 + 0.92A

5.0

mg/kg

4;t3 + 0.63

4.00 ±0.65A

10.0

mg/kg

6.25 + 0.12

:5'-:25,7-±;pv';5:2:^^

U-50,

^Significant time main effect indicating that the total
number of s

counts in the second 30-min

testing period was significant1y different from the
first 30-min testing period, P<0.05.

00
00
O
o
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Discussion

Results showed that U-5Dj4B8-treatment dtafflatically
increased the locomotor activity of i7-day-^oid rats.

However, U-50,488 had no effect on the stereotyped

sniffing of preweaniing rats.

In the 17-day-'c5ld rat 5.0

mg/kg U-5Q,488 prodticed a consistent level of loeomotor

activity across the testing session.

In SOr-day-old

rats, 5.0 mg/kg U-50,488 produced a rapid deeiine in
locomotor activity, while having no effect on
stereotyped sniffing.

lased on these reSuIts the 5.0

mg/kg dose of U-50,488 was used in subsequent

All doses of amphetaraine and NPA increased the
loComotor activity of l7-day-Gld rats.

Importantly,

high doses of a DA agonist can induce stereotypical

behavior in the rat, often masking a drug's locomotor
activating effects.

Therefore, based on these results

2.5 mg/kg amphetamine and i.O mg/kg NPA were used for
future experiments.
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Experiment' 2 ■
The Effects of the DA Antagonist

on U^50,48S-Induced Behavior&

; . in' '!7-Day-Old'-Rats
■
r,'
This experiment was designed to determine whether
U-5G,488 works threugh a dopaminergic mechanise.

More

specificaliy, if flapenthixol blocked U-50,488's
behavioral effects it would suggest that U^SO,488
increases activity by enhancing DA funetionihgi
Method

Subjects.

Forty-bight male and female 17-day-old

Sprague-Dawley albino rats {HarIan) were used.
Procedure.

Six groups of l7-day-old rat rats (n =

8) received an acute injection of the dopamine receptor
antagonist flupenthixol (0, 0.025, 0.1, 0.4, or 0.8
mg/kg) 30 min prior to behavioral testing.

The same

rats then received U-50,488, NPA, or amphetamine

immediately prior to a 60-min behavioral testing
session.,, ^
Results

Line-crosses.

pverall, rats pretreated with 0.4 or

0.8 mg/kg flupenthixol had significahtly fewer 1ine

crosses than salihe-pretreated rats (ise^ Fig^^

[Condition main effect, F(4,35)=37.43, P<0.001; and
Tukey tests^ P<0.05].

Pretreatment with 0.8 mg/kg

flupenthixol significantly reduced U-50,4S8-induced
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loconlotor activity on each of the testing blocks

[Condition X Time interaction, F(20,175)=4.48, P<0.001;
and Tukey tests, P<0.05].

Furthermore, pretreatment

with 0.4 mg/kg flupenthixol attenuated U-50,488-induced

locomotor activity across the last four testing blocks
[Tukey tests, P<0.05],

Neither 0.025 or 0.1 mg/kg

flupenthixol had any significant effects on U-50,488
induced locomotor activity.

Stereotyped sniffing.

Overall, the total number of

sniffing counts declined from the first to second 30-min

testing period (see Table 5) [time main effect,
F(1,35)=15.31, P<0.05].

However, there were no

significant differences due to condition.
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FIGURE/CAPTION,

Figure 6.

■

Mean number of line-crosses during the 60-min

behavioral testing session.

The 17^day-6ld hats {n = 8)

were injec;ted with flupenthixol (0.025, 0.1, 0.4, or 0.8

mg/kg, i.p.) 60 min prior to behayipral testing.

Rats

were then given U^50,488 (5.0 mg/kg, s.c.), amphetamine
(2.5 mg/kg, i.p;), NPA (1.0 siig/kg, i - P.) or saline

immediately prior to testing.
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Table 5. Mean stereotyped sniffing counts (+SEM) of 17
day-old rats given U-50,488 (5.0 mg/kg) 30 min after
!<
treatment with flupenthixol (0.0—0.8 mg/kg).
Behavioral testing occurred immediately after U-50,488
treatment and was recorded for 60 min (divided into
two
O
30-min testing periods).

Stereotyped Sniffing Counts

Flupenthixol

First 30 Min

Second 30 Min

0.0 mg/kg

2.75

+

1.37

1 .63 •'±

0.025 mg/kg

2.63

+

1.29

0.88

0.1 mg/kg

1.13

+

0.44

0.25 + 0.25A

0.4 mg/kg

1 .25

+

0.41

0.63

+

0.63A

0.8 mg/kg

0.00

+

0.00

0.00

+

O.OOA

+

0.52A

^Significant time main effect indicating that the total
number of sniffing counts in the second 30-min
testing period was significantly different from the
the first 30-min testing period, P<0.05.
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Discussion

The goal of this experiment was to determine the

effects of flupenthixol, a DA antagonist, on U,50-488
induced behaviors.

Flupenthixol did produce a decline

in U-50,488-induced behaviors in the 17-day-old rat.

This decrease in activity suggests that U-50,488's
behavioral effects may work via a dopaminergic
mechanism.

However, it is possible that flupenthixol

may have decreased U-50,488-induced activity by a

general depression of motoric functioning.

Therefore,

subsequdnt experiments were done to further examine the

interaction between the kappa opioid and DA systems.

To

that end, rats were pretreated with the kappa receptor
agonist U-50,488, then received either the indirect DA

agonist amphetamine or the direct DA agonist NPA.

If

these drugs are working through a dopaminergic mechanism
one would predict that U-50,488 pretreatment would
potentiate DA agonist-induced activity.
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Experiraent 3a

The Effects of Afflphetamine of NEA on U-50 i 438^Induced
Behaviors in the 17-Day-Old Rat

The &oal of the present experiment was to determine

whether the kappa opioid and T)A agonists activatp
behavior through the same mechanism.

More^ specifically,

if U-50,488 potentiated amphetamine's and/or NPA's
locomotor activating effects it would suggest that these
drugs are ultimately activating the same pathways.
;■

Method

Sub.iects.

Forty-eight male a,nd female 17-day-old

Sprague-Dawley albino tats (Harlan) were used.
Procedures.

Six groups of 17-day-old rats (n = 8)

received an acute injection of U-50,488 immediateTy
pr-ior to a 60-min behavioral testing session.

Subjects

then received an acute injection of amphetamine, NPA, of

saline 30 min into the behavioral testing session.

One

hour after behavioral testing, rats were anesthetized
with phenobarbital and rapidly perfused with 4%

paraformuldehyde fpr later analysis of Eos

\immunbroaetivity.'';tt''
■ ■Result's-"'^

Line-crosses.

Overall. 17-day-old rats treated

with U-50,488 had significantly more line-crosses than
saline-1reated rats acroSs the initia1 three testing

blocks (see left panel, Figure 7) [Pre X Time
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interactibhj F(2;,92)=24;35, i^O.001; and Tukey tes
0.051.

P<

Interestingly, across the final three testing

blocks, NPA produced a progressive deeline in U-50,488

induced 1ine-crosses; v)hereas, amphetamine had no effect
on U-50,488-induOed activity (see upper graph, right
panel, Figure 7) [Pre X Post X Time interaction,

F(4,8,4)=7.95, ;p<0.0

tests, P<0.05].

^

By itself, NPA sigrxificantly increased the 1ine
crosses of saline-pretreated rats (lower graph, right
panel, Figure 7); howeyer, rats given both U-50,488 an
NPA did not differ from rats given NPA a1one [Pre X Post
X Time interaction, F(4,84)=7.95, PCO,001; and Tukey

testsj P<0.05].

Amphetamine alone also significahtly

;increa:sed the line-crosses Of saline-pretreated rats

(lowOr graph, right panel, Figure 7) [Tukey tests,
P<Q.05].

Rats given both U-sp,488 and amphetamine had

significantly more 1ine-crOsSeS than rats given
amphetamine alone [Tukey tests, P<0.05] (right POhO1,
;-'Figure-'7
Stereotyped sriiffing.

The were no significant

differences between saline- Or U-50,488-pretreated rats

during the initial 30-mih testing period.

Overali; U-

50,488-treated rats had significantly fewer stereotyped
Sniffing counts than saline-pretreated rats during the
final testing period (see Table 6) [pre main effect,
=4.42, P<0.05].

This effect was entifely due to
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c

NPA's actions however, as rats given NPA had
significantly more stereotyped sniffing counts than the

saline controls during the second SO-min testing period

[post main effect, F{2,47)=65.17, P<0.001; and Tukey
tests, P<0.05].
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FIGURE CAPTION

Figure 7.

Mean number of line-crosses during the 60-min

behavioral testing session.

The i7-day-old rats (n = 8)

were injected v/ith U-50,488 (5.0 mg/kg, s.c.) or saline
immediately prior to behavioral testing.

Rats were then

injected w11h amphetamine ( .5 mg/kg ^ i.p.)^ NPA (1.0

mg/kg, i.p.) or saline 30 min into the testing session.
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Table 6.

Mean stereotyped sniffing counts (+SEM) of 17

day-old rats given U-50,488 (5.0 mg/kg) or saline
immediately prior to behavioral testing. NPA (1.0
riig/kg), amphetamine (2.5 mg/kg) or saline were then
administered 30 min into the testing session, with
sniffing being assessed for an additional 30 min.

Stereotyped Sniffing Counts

Drug Treatment

First 30 Min

Second 30 Min

U-50,488/NPA

2.00

+

0.82

30.72

+

5.88AB

Saline/NPA

0.75

+

0.49

42.62

+

5.28®

U-50,488/Sa1ine

1.75

+

0.52

1.25

+

0.86A

Saline/Saline

1.12

+

0.66

0.62

+

0.49

U-50,488/Amphetamine

1.12

+

0.39

2.00

+

1.10 A

Saline/Amphetamine

1.50

+

0.53

8.37

+

2.34

^Significant pre main effect indicating that the U50,488-pretreated rats were significantly different
from the saline-pretreated rats, P<0.05.
^Significant post main effect indicating that the NPAtreated rats were sigificantly different from the
amphetamine- and saline-treated rats, P<0.05.
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Discussion

Results showed that amphetamine had only trivial
effects on U50-488's stereotyped sniffing and locomotor

activating effects.

Unexpectedly, NPA dramatically

reduced U-50,488-induced locomotor activity.

When given

alone, NPA increased the stereotyped sniffing of both U
50,488- and saline-pretreated rats.
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;

/;:;ExpeTim;erit\

;■

The Effects of Amphetataine or NPA ott U-50,488-Induced

Behaviors in' the 8O-0ay-^dld Rat
Method

>,

Subiects.

Forty-eight male and female 80-day-old

Sprague^Dawley aibino rats (Har1an) were used.
Procedures.

Six groups of 80-day*-old rats (n = 8)

received ail aeute injectioh(of U-5Q,48

immediately

prior to a 1 hr behavioral testing sessiont

Subjects .

then receiyed an acute injection of amphetamine, NPA, or
saline 30 min into the behaviorai testing session.

One

hour after behavioral testing, rgts were anesthetized
with phenobarbital and rapidly perfused with 4%

paraformaldehyde testing for later analysis of Fos
immunoreactivity.
Results

'
■

Line-crosses.

During the initial three testing

blocks there were no significant differences between 80
day-old rats treated with either U-50,488 or saline (see
left panel. Figure 8),

During the final three testing

blocks amphetamine-treated rats had significantly more
1ine-crosses than rats receiving saline (see right
panel. Figure 8) [post main effect, F(2,42)=9.40,
P<0.001; and Tukey tests, P<0.05].

During the fourth

testing block rats given U-50,488 alone had

significantly fewer line-crosses than al1 other rats
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(see right panel. Figure 8) [Pre X Post X Time

interaction, F(4,84)-3.16, P<0.05• and Tukey tests,
P<0.05].

During the final two testing blocks, rats

receiving amphetamine alone had significantly more linecrosses than the saline groups [Tukey tests, P<0.05].
Stereotyped sniffing.

During the initial testing

period there were no significant differences in sniffing
between the U-50,488- and saline-treated rats (see Table

7).

During the final testing period, rats pretreated

with U-50,488 had significantly fewer stereotyped
sniffing counts than saline-pretreated rats [pre main

effect, P(1,47)=5,68, P<0.05].

This effect was entirely

due to NPA's actions, as rats given NPA had

significantly more stereotyped sniffing counts than

their saline controls during the final testing period

[post main effect, P(2,47)=157.81, P<0.001; and Tukey
tests, P<0.05].
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FIGURE CAPtlbN;
Figure 8.

Mean number of line-cfosses during the 60-m^^^^f^

behavioral testing sessidn.

The

rats (n = 8)

were injected with U-50,488 (5,0 mg/kg, s.c.) or saline
immediately prior to behavioral testing.

Rats were then

injected with amphetamine (2.5 mg/kg, i.p.), NPA (1.0

i.p.) or saline 30 min intp the testing session.
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Table 7. Mean stereotyped sniffing counts (+SEM) of 80
day-old rats given U-50,488 (5.0 mg/kg) or saline
immediately prior to behavioral testing. NPA (1.0
mg/kg), amphetamine (2.5 mg/kg) or saline were then
administered 30 min into the testing session, with
sniffing being assessed for an additional 30 min.

Stereotyped Sniffing Counts

Drug Treatment

First 30 Min

Second 30 Min

6.79AB

U-50,488/NPA

4.62 + 2.56

50.00

Saline/NPA

5.38

+

1.39

66.13

+

2.83B

U-50,488/Saline

3.88

+

0.90

3.38

+

1 .84A

Saline/Saline

6.38

+

2.04

5.38

+

2.31

U-50,488/Amphetamine

6.87

+

2.21

4.00

+

0.92A

Saline/Amphetamine

7.63

+

2.23

6.12

+

2.91

^Significant pre main effect indicating that the U
50,488 groups were significantly different from the
saline-pretreated groups, P<0.05.

^Significant post main effect indicating that the NPAtreated groups were significantly different from all
other groups, P<0.05.
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Discussion

As predicted, U-50,488 did not enhance the

behavipralo

of the 80-day-old rat.

Amphetaniine did enhance the locomotor activity of the
adult rats, while having no effect on stereotyped

sniffing.

Conversely, NPA increased the sniffing of 80

day-old rats, while having no effect on locomotor
activi.ty. ,
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-.Experiment, 3c

The Effects of U-50,488, Amphetamine, and NPA,
on Eos Immunoreactivity in the Preweanling and Adu11 Rat
Method

Sub.iects.

Ninety-six male and female 17- and 80

day-bid Sprague-Dawley rats (Harlan) were used.

These

rats were subjects from iExperiments 3a and 3b.

Supplies.

The primary antibody was a monQclonai

antibody made to the N-terminal end of the Eos molecule

in mouse myeloma cells (generously supplied from the

laboratpries of Era,nk Sharp and Stephen sagaf);

This

primary antibody recoghizes EbS and not Eos-related
antigens.

The secondary antibody was a biotinylated

mouse-anti-rat secondary antibody (Vector Laboratories,
Inc., Burlingame, CA, USA).

An avidin-biotin

horseradish peroxidase conjugate from an ABC horse kit

was also used (Vector Laboratories, Inc.).
Procedures.

Eollowing a postfixation period, 100

micron sections were cut from each brain using a
Vibratome 1000 (Ted Pella, Inc., Redding, CA, USA).

The

sections were washed three times with 0.1 M phosphate

buffer (PB) before being incubated with the Eos primary
antibody at a 1:50,000 dilution in HSS (0.1 M PB
containing 2% horse serum, 0.1% triton-XlOO, and 0.1%
bovine serum albumin).

Sections were incubated in the

primary antibody for 48-72 hr.
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Control sections from

each rat were run in the absence of the primary

antibody.

All sections were then washed three times in

PB and incubated with a biotinylated mouse-anti-rat

secondary antibody for 2 hr (1:1Q,66d di1ution in HSS),
Sections were washed th

imes in PB and incubated for

2 hr in avldiri-biotin-^horseradish peroxidase cohjugate
from ABC horse kitsr

Sections were then washed three

more times and the Fos protein was visualized using
3,3'-diaminobenzidine tetra,hydrochlor^^
peroxide.

hydrogen

Sections were then rinsed in PB and mounted

on chrom-alum slides.

The slides were then air dried,

dehydrated, and covers1ipped with permount.
lasted 5 min.

Al1 washes

This general procedure was based on the

method of Sharp et al. (1989).

A total of 6 rats from each drug treatment group
were randomly chosen for analysis of Fos

immunoreactivity.

Similar coronal sections from each

rat were selected for quantitative analysis.

The number

of distinguishable immunoreactive nuclei present within

the core and shell of the nucleus accumbens (1.7 A), the

dorsal and ventral striatum (1.7 A), amygdala (3.8 P),
septal area (0.3 P), olfactory tubercules (1.7 A),
anterior cingulate cortex (1.7 A), stria medullaris (3.8

P), habenula (3.8 P), posterior hypothalamus (3.8 P),
preoptic area (1.7 A), rhomboid nucleus (3.8 P), zona

incerta (3.8 P), and piriform cortex (1.7 A) iyere
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manually counted using a magnifieatidh

.

(The

numbers in parentheses represent sections either

anteriQi or jpbsterior to bregma, accbrdiilg to the rat

brain atlas of Pellegrino & Cushmahi 19l67> )
region, specific sam^^

of the saraple area^ b^^

At each

areas were counted with the size

X 10 mm.

Results

Effects of U-50.488. amphetamine, and NPA on Fos

immunoreaetivity in i7-day-old rats.

U-50,488 enhanced

Fos immunoreacfiyity in specific brain regions of the
preweanling rat (see Figures 9-21).

That is, compared

to rats given saline, U-50,488 signifleantly enhanced
the number of Fos-positive nuclei in the striatum,

olfactory tubercles, piriform cortex, habenula, preoptic
area, amygdala, stria medullaris, cingulate cortex, and
septal area [1(10)=3.73, P<0.01; t(10)=3.21, P<0.01;

t(10)=2.24, P<0.05; t(10)=3.09, P<0.05; t(10)=3.72,
P<0.01; t(10)=2.99, P<0.05; t(10)=4.28, P<0.01; t(10)=
3.52, P<0.01; t(10)=3.44, P<0.01, respectively].
Moreover, collapsed across the posttreatment, 17-day-old
rats given U-50,488 had significantly more Fos-positive

niiclei than saline-treated rats in the striatum,

piriform cortex, habenula, preoptic area, amygdala, and
septal area [pre main effects, P(1,35)=17.29, P<0.001;
=7.33, P<0.05; F(1,35)=34.65, P<0.001;
=26.77, P<0.001; P(1,35)=5.74, P<0.05;
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F(1,35)=23,42, P<0.001, respectively].
Amphetamine and NPA also had their own effects on
Fos immunoreactivity.

For example, amphetamine

significantly attenuated U-50,488-induced Fos expression
in the olfactory tubercles (see Figure 10) [Pre X Post
interaction, F(2,35)=5.38, P<0.01; and Tukey tests,

P<0.05].

Similarly, NPA significantly depressed U-

50,488-ihduced Fos expression in the striatum [Tukey
tests, P<0.05].

Conversely, amphetamine and NPA

enhanced the number of Fos-positive nuclei in the

piriform cortex (see Figure 13) [post main effect,

P(1,35)-3.17, P<0.65].

In the cingulate cortex, 17-day

old rats given ampheta.mine alone had significantly more
Fos-positive nuclei than rats in the saline control

group [Pre X Post interaction, P(2,35)=3.58, P<0.05; and
Tukey tests, p<0.05].
Effects of amphetamine. NPA. and U-50.488 on Fos

immunoreactivity in 80-day^old rats.

In general, U

50,488 did not affect Fos expression in 80-'day-old rats.
The one exception was the ha.benula, where there were

more Fos-ppsitive nuclei in the U-50,488-pretreated
rats than in the saline-pretreated rats (see Figure 22)

[pre main effect, P(1,35)=6.62, P<0.05].

NPA signifrcahtly;increased Fos expression in the
piriform cortejt, an effect attenuated by U-50,488

bretreatment (see Figure 23) tPre X Post interaction.
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F(2,35)=6.37, P<0.01; arid Tukey tests, P<0.05}.

NPA

also reduced the mean number of Fos-positive nuclei in
the olfactory tubercles, however this was apparent in

both the saline- and U-50,488-pretreated rats (See
Figure 24) [post main effect, P(2,35)=4.34, P<0.05; and
Tukey tests, P<0.05].

Amphetamine only affected Fos expression
in the zona incerta,

In this particular region,

amphetamine decreased the number of Fos-positive nuclei
relative to the saline-treated rats (see Figure 25)

[post main effect, P(2,35)=3.87, P<0.05; and Tukey
tests, P<0.05].
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FIGURE CAPTION

Figure 9.

Mean number (+SEM) of Fos-positive nuclei

throughout the striatum of the 17-day-old rat (n = 6).
The rats were sacrificed 60 min after behavioral testing
and were the same rats as those described in Figure 7.

^Significant t-test indicating that the U-50,488/saline
group was significantly different from the saline/saline
group, P<0.01.

^significant pretreatment main effect

indicating that U-50,488-pretreated rats were

significantly different from saline-pretreated rats,
P<0.001.
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Figure 10. Mean number (+SEM) of Fos-positive nuclei

throughout the olfactory tubercles of the 17-day-old rat
(n = 6).

The rats were sacrificed 60 min after

behavioral testing and were the same rats as those

described in Figure 7.

^Significant Pre X Post

interaction indicating that the U-50,488/saline and U
50,488/NPA groups were significantly different from

their respective saline-pretreated control groups,

P<0.05.

''Significant Pre X Post interaction indicating

that the U-50,488/amphetamine group was significantly
different from the U-50,488/saline group, P<0.05.
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Figure 11.

Mean number (+SEM) of Fos-positive nuclei

throughout the piriform cortex of the 17-day-old rat {n
= 6).

The rats were sacrificed 60 min after behavioral

testing and were the same rats as those described in
Figure 7.

^Significant t-test indicating that the U

50,488/saline group was significantly different from the
saline/saline group, P<0.05.

^Significant pre main

effect indicating that U-50,488-pretreated rats were
significantly different from saline-pretreated rats,

P<0.05.

^Significant post main effect indicating that

the amphetamine- and NPA-treated rats were significantly
different from their saline-treated controls, P<0.05.
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Figure 12.

Mean number (+SEM) of F'os-pdsitive nuclei

throughout the habenu1a of the 17-day-oId rat (h - 6).
The rats were sacrificed 60 min after behavioral testing
and were the same rats as thoSe described in Figure 7.

^Sighificant t-test inclicatihg that thd 0^50 v488/sali

group was significantly different from the saline/salihe
group, P<0.05.

ASignificant pre main effeet indicating

that U-50,488^pretreated rats were significantly
different from the saline-pretreated rats, P<0,0U1•
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Figure 13.

Mean number (+SEM) of Fos-positive nuclei

throughout the preoptic area of the 17-day-old rat (n =
6).

The rats were sacrificed 60 min after behavioral

testing and were the same rats as those described in
Figure 7.

®^Significant t-test indicating that the U

50,488/saline group was significantly different from the
saline/saline group, P<0.01.

^Significant pre main

effect indicating that U-50,488-pretreated rats were
significantly different from saline-pretreated rats,
P<0,001.
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Figure 14.

Mean number (+SEM) of Fos-positive nuclei

throughout the amygdala of the 17-day-old rat (// = 6).
The rats wefe^^

60 min after behavioral testing

and were the same rats as those described in Figure 7. ;

^Significant t-test indicating that the U-50,488/saline
group was significdntly different from the saline/saline
group, F<0.05.

^Significant pre main effect indicating

that U-50,488-pretreated rats were significantly
different from saline-pretreated rats, P<0.05.
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Figure 15.

Mean number (+SEM) of Fos-posi1

nuclei

throughbut the stria medullaris of the 17-day-old rat (n

= 6).

The rats were sacrificed 60 min after behavioral

testing and were the same rats as those described in
Figure 7.^

®Significant t-test indidating that the U

50 j 488/saiine group was significahtly different from the
saline/saline group, P<0.01.
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Figure 16.

Mean number (+SEM) of Fos-positive nuclei

throughout the cingulate cortex of the 17-day-ol<i rat (n
= 6).

The rats were sacrificed 60 miri after behavioral

testing and were the same rats as those described in
Figure 7.

^Significant t-test indicating that the

50 ^ 488/saline group was Significahtly different from the

saline/saline group, F<0-05.

^'Significant Pre X Post

interaction indicating that the saline/amphetamine group

was significantly different from the saline/saline
group, P<0.05.
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Figure 17.

Mean number (+SEM) of Fos-positive nuclei

throughout the septal area of the 17-day-old rat (n =
6).

The rats were sacrificed 60 min after behavioral

testing and were the same rats as those described in

Figure 7.

^Significant t-test indicating that the U

50,488/saline group was significantly different from the
saline/saline group, F<0.01.

^Significant pre main

effect indicating that U-50,488-pretreated rats were

significantly different from saline-pretreated rats,
P<0.001.
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Figure 18.

Mean number (+SEM) of Fos-positive nuclei

throughout the nucleus accumbens of the 17-day-old rat
(n = 6).

The rats were sacrificed 60 min after

behavioral testing and were the same rats as those
described in Figure 7.
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Figure 19.

Mean niimber (+SEM) of Fos-positive nuclei

throughout the posterior hypothalamus of the 17-day-old
rat (n = 6).

The rats were sacrificed 60 min after

behavioral testing and were the same rats as those
described in Figure 7.
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Figure 20.

Mean number (+SEM) of Fos-positive nuclei

throughout the rhomboid nucleus of the 17-day-old rat (n
= 6).

The rats were sacrificed 60 min after behavioral

testing and were the same rats as those described in
Figure 7.
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Figure 21.

Mean number (+SEM) of Fos-positive nuclei

throughout the zona incerta of the 17-day-old rat (n =
6).

The rats were sacrificed 60 min after behavioral

testing and were the same rats as those described in
Figure 7.
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Figure 22. Mean number (+SEM) of Eos-positive nuclei

throughout the habenu1a of the 80-day-oId rat (^ = 6).

The rats were sacrificed 60 min after behavioral testing
and were the same rats as those described in Figure 8.

''^Significant pre main effect indicating that U-50,488^
pretreated rats were sighifieantly different from

salinb--pretreated fats, f^OiObi.
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Figure 23.

Mean number (+SEM) of Fos-positive nuclei

throughout the piriform cortex of the SO-day-old rat (n
=6).

The rats were sacrificed 60 min after behavioral

testing and were the same rats as those described in

Figure 8.

^Significant Pre X Post interaction

indicating that the U-50,488/NPA group was significantly
different from the saline/NPA group, P<0.05.

''Significant Pre X Post interaction indicating that the
saline/NPA group was significantly different from the
saline/saline group, P<0.05.
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Figure 24.

Mean number (+SEM) of Fos-positive nuclei

throughout the olfactory tubercles of the 80-day-old rat
{n = 6).

The rats were sacrificed 60 rain after

behavioral testing and were the same rats as those

described in Figure 8.

^Significant post main effect

indicating that the NPA-treated rats were significantly
different from their saline-treated controls, P<0.05.
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Figure 25.

fig)[jre;::gaption^:- '- ;^

■

Mean number (+SEM) of Fos-positive nuclei

throughout the zona ihcerta of the 80-day-old rat (n =
6).

The rats were sacrificed 60 min after behavioral

testing and werd^^^

Figure 8.

as thpse described in

®Significant post main effect inidieating that

the NPAvtfeated rats were significantly diffefent f
their saline-treated controls, P<0.05;
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Figure 26.

Mean number (+SEM) of Fos-positive nuclei

fhroughout the striatum of the 80-day-old rat {n = 6)•
The rats were sacrificed 60 min after behavioral testing
and were the same rats as those described in Figure 8.
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Figure 27.

Mean number (+SEM) of Fos-positive nuclei

throughout the preoptic area of the 80-day-old rat (n
6).

The rats were sacrificed 60 min after behavioral

testing and were the same rats as those described in
Figure 8.
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Figure 28.

Mean number (+SEM) of Fos-positive nuclei

throughout the amygdala of the 80-day-old rat (n = 6).
The rats were sacrificed 60 min after behavioral testing
and were the same rats as those described in Figure 8,
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Figure 29.

Mean number (+SEM) of Fos-positive nuclei

throughout the septal area of the 80-day-old rat (n =
6).

The rats were sacrificed 60 min after behavioral

testing and were the same rats as those described in
Figure 8.
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Figure 30.

Mean number (+SEM) of Fos-positive nuclei

throughout the cingulate cortex of the 80-day-old rat {n
= 6).

The rats were sacrificed 60 min after behavioral

testing and were the same rats as those described in
Figure 8.

115

80—Day—Olds
TOO

100

I

X
CD
-M

80

^ AMPH

-80

H NPA

o

o

I Saline

60

-60

40

-40

20

-20

0

0

CD
-M

_o
=3

cn
c

O
Control

Soline

U50488

VO

FIGURE CAPTION

Figure 3i.

Mean number (+SEM) of Fos-positive nuclei

throughout the stria medullaris of the 80-day-old rat (n

- 6).

The rats were sacrific

60 min after behavioral

testing a.nd were the same rats as thbse described in
Figure 8.

117

80—Day—Olds
150

150
I Saline

cn

AMPH
D

NPA
-100

— 100
13
CD

00

D

-50

50

(/)

Control

Saline

U50488

FIGURE CAPTION

Figure 32.

Mean number (+SEM) of Fos-positive nuclei

throughout the nucleus accumbens of the 80-day-old rat
(n = 6).

The rats were sacrificed 60 min after

behavioral testing and were the same rats as those

described in Figure 8.
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Figure 33.

Mean number (+SEM) of Fos-positive nuclei

throughout the posterior hypothalamus of the 80-day-old
rat (n - 6)•

The rats were sacrificed 60 min after

behavioral testing and were the same rats as those
described in Figure 8.
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Figure 34. Mean number (+SEM) of Fbs-positlveriuelei

thrpugliout tbe rhomboid nucleus Of the 80-day-old rat (n
- 6).

The rats were sacrificed 60 min after behavioral

testing and were the same rats as those described in
■Eigure. .8.. .
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Piscussion

The 17-day-old rats treated with U-5d,488 displayed
an increased number of Fps-positive nuclei in several
brain regions, suggesting Ipcatidns where the DA and

kappa opioid systems may ihteract.

Interestingly, U

50,488 dramatically enhanced Fos expression in the
striatum of the 17-day-old rat/

This is partidularly

important because the striatum is known to be involved
in the mediation of Ibcomotor activity, rearing, and

grooming (Arnt, 1987; Bofdi et al., 1989).

In the

present study, NPA dramatically reduced U-50,488-induced
Fos expressioh in the striatum.

This pattern of

neuronal activity correlates with behavior, as NPA
depressed U-50,488-induced locomotor activity in the

preweanling rat (see Experiment 3a).

Similarly,

amphetamine decreased U-50,488-induced Fos expression in

the olfactory tubercles of the 17-day-old rat.

The

olfactory tubercles are involved in learning and memory
and have been associated with conditioned place

aversions (Ehret & Buckenmaier, 1994).

Although

speculative, it is possible that these Fos effects may

be due to amphetamine attenuating U-50,488's aversive
properties.

Several other brain regions of the 17-day-old rat

displayed increased Fos immunoreactivity in response
to U-50,488.

Fos expression was enhanced by U-50,488 in
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the cingulate cortex, septal area, and preoptic area.
These brain regions mediate a variety of behaviors.

For

example, the septal area mediates analgesia, aversions,

aggression, and locomotor activity (Noltej 1981; Roeling
et al., 1994; Schwarting & Huston, 1992).

The cingulate

cortex arid preoptic area are involved the mediation of

emotion, memory, reproductive behaviors, and motoric

functioriing (Agmo & Villalpando, 1995; Kopb & Swerdlow,
1988; Vogt, Finch, & Olson, 1992).

However, common to

each of these brain regions is participation in the

modulation of lOcomotor activity.

U^50,488's neuronal

activation in these areas is consistent with the

increased locomotor activity displayed after 11-50,488
treatment in the 17-day-old rat (see Experiments la and
3a). ■ ■

U-50,488 also enhanced Fos expression in the
piriform cortex, habenula, amygdala, and septal area of
the 17-day-o1d rat.

These brain regions are irivo1ved in

the mediation of a number of behaviors.

For example,

the piriform cortex and habenula mediate olfactiori,
conditioned taste aversions, ari^lsesia, and sexual
activity (Hasselmo, 1995; Lee & Huang, 1988; Werka,
Skar, & Ursin, 1978).

The amygdala and septal area are

involved in conditioned place aversions, maternal
behavior, analgesia, and aggression (Schwarting &
Huston, 1992; Umino, Nishikawa, & Takahashi, 1995).
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Overall, these brain areas share the common feature of

being involved in the mediation of analgesia and
aversions.

It is known that kappa opioid agonists

produce analgesia and aversions in the preweanling rat

(Barr, 1992; Barr et al., 1986, 1994); therefore, it is
not surprising that U-50,488 produced Fos expression in
these brain regions.
Amphetamine and NPA also affected Fos

immunoreactivity in the preweanling rat.

Both of the DA

agonists increased Fos expression in the piriform

cortex, an area involved in the mediation of sniffing
and exploratory behavior (Hasselmo, 1995; Nolte, 1981).

Thus, amphetamine and NPA increase sniffing and
locomotor activity in 17-day-old rats, while
increasing Fos expression irl the piriform cortex.
Amphetamine also increased Fos induction in the

cingulate cortex of the preweanling rat.

Dopamine

receptor activation in the cingulate cortex enhances
locomotor activity (Agmo & Villalpando, 1995; Devinsky,
Morrell, & Vogt, 1995).
With one exception, U-50,488 did not increase Fos

immunoreactivity in 80-day-old rats.

In the habenula,

Fos expression was enhanced after U-50,488 treatment.
Neuronal activation in the habenula is involved in

olfaction, analgesia, sexual behaviors, and aversions.
U-50,488 is known to produce both conditioned place and
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x

taste aversions in the rat (Bart, 1992; Bechara & Van

der Kooy, 1987; Lee & Huang, 1988; Thorntpn & Davies,
1991).

Therefore, it is possible that U-5d,488's

aversive properties may be inediated in this area.

Alternatively, U-SO,488 attenuated NPA-induced sniffing,
so it is possible that Fos expression In the habenula

reflects sniffing or olfactory effects, rather than
aversions.

Consistent with the antagonistic relationship

displayed in the preweanling rat, U-50,488 also
attenuated NPA-induced Fos expression in the piriform
cortex of the adult rat.

The piriform cortex is an

olfactory relay center and this neuronal interaction

between U-50,488 and NPA coincides with U-50,488's
ability to depress NPA-induced sniffing (see Tables 3
and 6).

Treatment with DA Agonists alone also affected Fos
immunoreactivity in the 80-day-old rat.

For example,

amphetamine decreased Fos expression in the zona incerta
of the adult rat, an area involved in the modulation of

ingestive behaviors (Ricardo, 1981; Tonelli &

Chairaviglio, 1995).

NPA reduced Fos expression in the

olfactory tubercles of the 80-day-old rat.

The

olfactory tubercles are involved in mediating shiffing
and exploratory behavior (Hasselmo, 1995),

The fact

that amphetamine and NPA affected Fos expression in
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these brain areas is not surprising as these regions are
densely populated with dopamine receptors (DeutGh, Taniv
& Roth, 1985; Leibowitz & Rossokis, 1979; Stein/ Carr, &

Simon, 1990.) .v'
In summary, a numbdr of brain regions showed druginduced Fos expression.

Aithough we attempted to make

comparisons between regional Fos expression and
behavior, it is important to realize that such

comparisons must be interpreted with a great deal of
caution.

The brain regions showing Fps activity mediate

a variety of behaviors and, in many cases, it is very

speculative to 1ink drug-induced behavioral effects with
Fos.

Even so, U-50,488 did dramatically enhance Fos

expression in the striatum of the 17-day-old rat, an

effect blocked by NPA treatment.

This pattern of Fos

activity is consistent with NPA's effects on U-50,488

induced locomotor activity (see Experiment 3a)

When

considered together, these results suggest that the

striatum may be involved in the mediation of U-50,488's

locombtor activating effects.
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Experi-ment; 4

The Behavioral Effects of NPA on U--50,48S-In^^^^
Behaviors in 17-Day-Qld Rats
It was predicted that NPA and amphetainine would

potentiate u-50,488-induced locomotor actiylty in the
preweaniing rat.

In Experiment 3, however, a single

dose of NPA was found to attenuate U-5d,488-induced

behaviors in the 17-day-old rat, while amphetamine left
these behaviors unaffected.

A possible explanation for

these data ia that combined treatment with U-50,488 and
NPA produced intense stereotypical behaviors not
measured in the last experiment.

To assess this

possibility, U-50,488-pretreated rats received lesser

doses of NPA that should produce locomotor activity
without inducing stereotypical behaviors.
Methods

Subi ects.

Eighty male and female 17-day-old

Sprague-Dawley albino rats (HarIan) were used.
Procedures.

Ten groups of 17-day-old rats (n = 8)

received an acute injection of U-50,488 (5.0 mg/Rg,

s.c.) immediately prior to a 60-min behavioral testing
:session.

Rats then received an aCute injeCtion of NPA

(0.0, 0.001, 0.01, 0.1, or 1.0 mg/kg, i.p.) 30 min into
the testing session.
Results

Line-crosses.

During the initial three testing
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blocks rats given U-50,488 had significantiy more linecrosses than saline-treated rats (left jjanel. Figure 35)
[pre main effect, F(l,78)=470.08, P<0.001].

During the

final three testing blocks, NPA attenuated U-50,488
induced line-crosses in a dose-dependent manner (upper

graphs right panel. Figure 35) [Pre X Post interaction,
F(4,70)=12;02j P<0.001; and Tukey tests, P<0.05).

For

instance, the 1.0 mg/kg dose of NPA produced the
greatest decline in U-50,488-induced locomotor activity,
with 0.1 and 0.01 mg/kg NPA producing a moderate decline

in activity (see upper graph, right panel. Figure 35)

[Tukey tests, P<0.05].
In contrast, when given alone, NPA enhanced the

locomotor activity of the 17-day-old rats (see lower
graph, right panel. Figure 35) [Pre X Post interaction,
P(4,70)=12.02, P<0.001; and Tukey tests, P<0.05].

The

0.01 mg/kg NPA produced the' most line-crosses, with 0.1
and 1.0 mg/kg NPA producing a moderate amount of
activity (Tukey tests, P<0.05).
Stereotvped sniffing.

During the first testing

period, sniffing was not affected by U-50,488
pretreatment [U-50,488: 2.00 + 0•36; saline: 1.07 +
0.23].

Oyerall, U-50,488-pretreated rats had

significantly fewer sniffing counts than saline-

pretreated rats (see Table 8) [pre main effect,
F(1,79)=82.24, P<0.001].

Saiine-pretreated rats given
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0.01, 0.1, or 1.0 mg/kg NPA had significantly more
sniffing counts than rats receiving saline [Pre X Post
interaction, FC4,79)=13.82, P<0.001; and Tukey tests,
P<0.05].

U-50,488-pretreated rats given 0.01, 0.1, and

1.0 mg/kg NPA had significantly fewer sniffing counts

than similarly treated saline-pretreated rats [Tukey
tests, P<0.05].
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FIGURE CAPTION

Figure 35.

Mean number of line-crosses during the 60

min behavioral testing session.

The 17-day-old rats (n

= 8) were injected with U-50,488 (5.0 mg/kg, s.c.) or
saline immediately prior to behavioral testing.

Rats

then received NPA (0.001, 0.01, 0.1, or 1.0 mg/kg, i.p.)
or saline 30 min into the testing session.
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Table 8. Mean stereotyped sniffing counts (+SEM) of 17
day-old rats following treatment with NPA (0.0-1.0
mg/kg) 30 min after an initial injection of U-50,488
(5.0 mg/kg). Behavioral testing occurred immediately
after U-50,488 treatment and was recorded for 60-min

(divided into two 30-min testing periods)i Data
reported are from the second 30-min testing period.

All

doses are in mg/kg.

Drug Treatment

Stereotyped Sniffing Counts

Saline/Saline

0.00 + 0.00

U-50,488/Saline

0.37^^^^ +

Saline/0.001 NPA

5.37 + 1.59

U-50,488/0.001 NPA

; 2.87 +1.34

Saline/0.01 NPA

30.50 ± 6.36®^

U-50,488/0.01 NPA

3.12 + 1.25

Saline/0.1 NPA

48.75 + 4.80^^

U-50,488/0.1 NPA

8.62+5.52

Saline/1.0 NPA

61.37 ± 5.67^"

U-50,488/1.0 NPA

16.12 + 5.31

^Significant Pre X Post interaction indicating that
saline-pretreated rats given NPA were significantly
different from the saline/saline group, P<0.05.

^Significaht Pre X Post interaction indicating that
saline-pretreated rats given NPA were significantly
different from similarly treated U-50,488-pretreated
rats, P<0.05.
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Discussion

NPA increased stereotyped sniffing in salinepretreated rats in a dose-dependent manner: an effect
attenuated by U-50,488-pretreatment.

Conversely, NPA

produced a dose-dependent decrease in U-50,488-induced

loebmotpr activity.

Thus, contrary to the original

hypotheses, these resu11s suggesf an antagonistic

re1ationship betWeen U-50,488 and NPA.
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Experiment 5

The Behavioral Effects of Amphetamine

on U-50,488-Induced Behaviors in 17-Day-Old Rats
Methods

Subjects.

Eighty male and female 17-day-old

Sprague-Dawley albino rats (Harlan) were used.
Procedures.

Ten groups of i7-day-old rats (n = 8)

received an acute injection of U-50,488 (5.0 mg/kg,

s.c.) immediately prior to a 60-min behavioral testing
session.

Rats then received an acute injection of

amphetamine (0.0, 1.0, 2.5, 5.0, 10.0 mg/kg, i.p.) 30
min into the behavioral testing session.
Results

Line-crosses.

Overall. there was a general decline

in the total number of line-crosses across the final

three testing blocks (see upper graph. Figure 36) [time
main effect, F(2,70)=12.13, P<0.001; and Tukey tests,
i'<0.05].

However, the various doses of amphetamine had

inconsistent effects on U—50,488-induced locomotor

activity.

For example, during the fourth testing block,

1.0, 2.5, and 10.0 mg/kg amphetamine produced

significantly more iine-crosses than saline; whereas,
rats given 5.0 mg/kg amphetamine had fewer line-crosses

than rats receiving 1.0 or 10.0 mg/kg amphetamine (see
upper graph, right panel. Figure 36) [Post X Time

interaction, F'(8,70)=6.01, P<0.001; and Tukey tests.
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P<0.05).

During the fifth testing bipck, U-50,488

pretreated rats given 2.5 or 5.0 mg/kg amphetamine had

significantly fewer line-crosses than rats receiving
saline, 1.0, or 10.0 mg/kg amphetamine [Tukey tests^
P<0,05].

However, by the final testing block, only rats

given 2.5 mg/kg amphetamine had sighificantly fewer
line-crosses than rats receiving saline.

During the

final testing block there were no significant

differences between the various groups of amphetaminetreated rats.

Stereotyped sniffing.

Overall. amphetamine

enhanced the stereotyped sniffing of the U-50,488
pretreated rats (see right panel, lower graph. Figure

38) [post main effect, F(4,35)=15.30, P<0.001; and Tukey
tests, P<0.05].

There was a progressive increase in

stereotyped sniffing during the final three testing
blocks [time main effect, P(2,70)=24.26, P<0,001; and
Tukey tests, P<0.05].

During the fourth testing block

there were no significant differences between rats given

amphetamine or saline.

However, during the fifth and

sixth testing block rats given 5.0 and 10.0 mg/kg
amphetamine had significantly more sniffing counts than
rats given saline (see right panel, lower graph. Figure
38) [Post X Time interaction, P(8,70)=11.54, P<0.001;
and Tukey tests, P<0.05].

Not pntil the sixth testing

block did 2.5 mg/kg amphetamine produce significantly
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more sniffing than the saline group [Tukey tests,
P<0.05].
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FIGURE CAPTION

Figure 36.

Mean number of line-crosses and stereotyped

sniffing counts during the 60-min behavioral testing
session.

The 17-day-old rats {n = 8) were injected with

U-50,488 (5.0 mg/kg, s.c.) immediately prior to

behavioral testing.

Rats were then given amphetamine

(1.0, 2.5, 5.0, or 10.0 mg/kg, i.p.) or saline 30 min
into the testing session.
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Discussion

Amphetamine produced no definitive pattern of

action on U-50,488-induced line-crossing.

For example,

during the fourth and fifth testing blocks

1.0 mg/kg amphetamine produced more locomotor activity
than 5.0 mg/kg amphetamine.

By the final testing block

there were no significant differences between

amphetafliine-freated rats.

Therefore, while NPA appears

to antagonize U-50,488-induced behaviors, amphetamine's
actions on U-50,488-induced behaviors are more

uncertain.

To further examine how the DA and kappa

systems interact two subsequent experiments were done.
Rats were given amphetamine or NPA for five consecutive

days.

Following a two day wash-out period, chronically

treated rats received a challenge injection of U-50,488
and were tested for cross-sensitization.

If cross-

sensitization were found between the DA agonists and U
50,488 this would indicate that the behavioral actions

of these drugs are mediated through common dopaminergic
mechanisms.
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Experiment 6

Cross-Sensitization in the Preweanling Rat:
The Behavioral Effects of U-5G,488
Following Chronic Treatment with NPA

The goal of this study was to determine if kappa

opioid and DA agonists enhance locomotor activity
through the same mechanisms.

In Experiment 6, cross-

sensitization was used to further assess this

hypothesis.

Sensitization, apparent in both preweanling

and adult rats, is characterized by a progressive
enhancement of the behavior-activating effects of DA or

opiate agonists (see McDougall, Duke, Bolanbs, &

Crawford, 1994; Robinson & Becker, 1988; Vezina &
Stewart, 1989).

Several studies indicate that

behavioral sensitization to DA and opiate agonists is
produced by modifications in the functioning of

nigrostriatal DA neurons (see Hoffman & Wise, 1992;

Vezina & Stewart, 1989).

For example, amphetamine-

sensitized rats show enhanced striatal DA release in

response to amphetamine challenge (Kalivas, 1985;
Robinson & Becker, 1986).

Similarly, rats sensitized to

morphine show enhanced release, synthesis, and

metabolism of DA in the nucleus accumbens fpllowing an
acute injection of morphine (Kalivas, 1985; Kalivas &
Duffy, 1987).

Interestingly, some drugs will cross-sensitize to
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one another, suggesting that both drugs are acting on
the same systems,

For examp1e, rats sensitized with GBR

12909 (a DA uptake inhibitbr) show cross-sensitization
in response to cocaine (Baldo & Kelly, 1991; Tolliver &
Carney, 1994).

Similarly, amphetamine-sensitized rats

display a sensitized response to cocaine challenge
(Kalivas & Weber, 1988).

Xmpbrtantly, opiate and

DA agonists cross-sensitize to one another.

For

example, successive intra-ventral tegmental area
injections of amphetamine result in a sensitized

response to systemic morphine, an effect that is
reciprocal (Stewart & Vezina, 1987; Vezina & Stewart, :
1990).

Since amphetamine appears to induce behavioral

sensitization by modulating striatal DA functioning,
morphirie's ability to cross-sensitize suggests that

these drugs are ultimately working through the same

system.

Therefore, if U-SO,488 cross-sensitizes with

the DA agonists, this would provide evidence that these
drugs work through the same mechanisms.
Methods
Subiects.

Thirtv-two male and female 17-dav-old

Sprague-Dawley albino rats (Harlan) were used.
Procedures.

Four groups of 11-day-old rats (n = 8)

received injections of NFA (O.O or 1.0 mg/kg, 1.p.) for
five consecutive days.

GloSs-sOnM tizatioh was examined

two days 1ater as the preweanling rats (i.e., at 17 days
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of age) received an acute injection of U-50,488 (5.0
mg/kg, s.c.) or NPA (1:0 mg/kg, i /p.)

C

was

added to the behaviors being recorded.

A circle count

was recorded when the rat turned 360°, with the rear

paws as the center point of the circle.

Each day a 60

min behavioral tea ting session took piace immed iately
after drug treatment.

Statistics.

,

To analyze the behavioral data,

repeated measure ANOVAs yfere perform

acrbss the five

days of conditioning, with a separate ANOVA performed

for the test day.
produced

In 'brder to assess whether NPA
sensitization a series of t-tests

{P<0.05) were performed to examine how the saline-^ and

NPA-conditioned rats responded to a challenge dose of
NPA.. ■ ,
Results

Conditionihg; Effects of NPA on locomotor activitv.

Rats receiving NPA had significantly more line-crosses
than saline controls across conditioning {see Figure 37)
[conditioning main effect, F(1,30)=62.48, P<0.001].

Furthermore, NpA produced a progressive increase in

line-^crosses from the first to last day of Conditioning

(upper graph. Figure 37) [Gonditibning X Day
interaction, F(4,120)=29.19, P<0.001; and Tukey tests,
P<0.05].
Testing: Effects of U-50.488 challenge on locomotor
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activity in NPA conditioned rats.

On the test day

sensitization was apparent, as rats given NPA during
both conditioning and testing had significa.ntly more
line-crosses than rats given NPA on Only the test day

(see triangles, right panel, Figure 37) [t(14)=2.58,
P<0.05].

U-50,488 did not cross-sensitize with NPA,

since the two groups challenged with U-50,488 responded

similarly oh the test day (see boxes, right panel.
Figure 37).

On the test day, rats given U-50,488 had

significantly more 1ine-crosses than rats given NPA (see

right panel, Figure 37) [Condition X Test interaction,
F(1,31)-7.28, P<0.05; and Tukey tests, P<0.05].
Conditioning: Effects of NPA on stereotvped

sniffing.

Overall, rats receiving NPA had significantly

more stereotyped sniffing counts than saline-treated
rats (see Figure 38) [conditiohing main effect,

P(1,30)=37.47, P<0.001].

NPA produced a progressive

increase in sniffing over the last three days of

conditioning (upper graph. Figure 38) [Conditioning X

Day interaction, P(4,120)=38.17, P<0.001; and Tukey
tests, P<0.05].
Testing: Effects of U-50.488 challenge on

stereotvped sniffing in NPA—conditioned rats.

On the

test day, NPA-conditioned rats displayed a sensitized

response to N^A.

Specifically, when challenged with

NPA, rats conditioned with NPA had significantly more
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stereotyped sniffing counts than rats conditioned with

saline (see triangles, right panel. Figure 38)

[t(14)=3.01, P<0.01].

On the test day, regardless of

conditioning, U-50,488 challenge failed to produce any
stereotyped sniffing.

Thus, rats given NPA on the test

day had significantly more stereotyped sniffing counts

than rats receiving U-50,488 (see right panel. Figure
38) [Conditioning X Test interaction, F(1,31)=9.45,
P<0.05; and Tukey tests, P<0.05].

Conditioning: Effects of NPA on circling.

During

conditioning, NPA produced a small, but significant,
increase in circling when compared to saline-treated

rats (upper graph. Figure 39) [conditioning main effect,
P(l,16)=11.64, P<0.05].
Testing: Effects of U-50.488 challenge on circling

in NPA-conditioned rats.

On the test day, rats

conditioned with NPA failed to display a sensitized

circling response after NPA challenge (see triangles,
upper right panel. Figure 39) [t(14)=1.08, P>0.05].

When given alone, U-50,488 failed to produce circling;
however, NPA-conditioned rats challenged with U-50,488
had significantly more circling counts than all other

groups (see box, upper right panel. Figure 39)

[Conditioning X Test interaction, P(1,24)=21.42,
P<0.001; and Tukey tests, P<0.05].
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FIGURE CAPTION

Figure 37.

Mean number of line-crosses of rats given

five daily injections of NPA (1.0 mg/kg, i.p.) or Saline
starting at 11 days of age (n = 8).

At 17 days of age

(i.e., after a 2-day interval), rats given successive
saline or NPA injections were then given a single

challenge injection of U-50,488 (5.0 mg/kg, s.c.) or NPA
(1.0 mg/kg, i.p.).
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FIGURE CAPTION

Figure 38.

Mean number of stereotyped sniffing counts

of rats given five daily injections of NPA (1.0 mg/kg,

i.p.) or saline starting at 11 days of age (n = 8).
17 days of age (i.e., after a 2-day interval), rats
given successive saline or NPA injections were then

given a single challenge injection of U-50,488 (5.0
mg/kg, s.c.) or NPA (1.0 mg/kg, i.p.).
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Figure 39.

Mean number of circling counts of rats given

five daily injections of NPA (1.0 mg/kg, i.p.) or saline
starting at 11 days of age {n = 8).

At 17 days of age

(i.e., after a 2-day interval), rats given successive
saline or NPA injections were then given a single
challenge injection of U-50,488 (5.0 mg/kg, s.c.) or NPA

■(:f.O'- mg/kg, /i..p,.

152

40

40Test Day

NPA During Conditioning

30

30

20

10

10
. c
•

"o

0

Test Day

Soline During Conditioning

b
30

30
▲ NPA

20

20

■ U50

0

10

0

-©
11

©
12

©
13

©
14

Age

153

©
15

Discussion

No evidence for cross-sensitization between NPA and

U-50,488 was apparent.

On the test day, rats

conditioned with NPA did display sensitized Ibcomotor
activity and stereotyped sniffing.

Interestingly, U

50,488 challenge significantly enhanced circling in NPA-

conditioned rats.

These results support the findings of

earlier experiments (i.e.. Experiments 3a and 4)
suggesting that a generally antagonistic relationship
exists between U'-50,488 and NPA.
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Experiment 7

Cross-Sensitization

Preweanling Rat:

The Behavioral Effects of U-SO,488^^^^

'

Following Chronic Treatment with Amphetamine
Methods ■

Subiects

Thirtv-two male and female 17-day-old

Sprague-Dawley albino rats (HarIan) were usedv
Procedures.

Four groups of 11-day-old rats {n = 8)

received injections of amphetamine (0.0 or 2.5 mg/kg,
i.p.) for five consecutive days.

Crpss-sensitization

was examined two days later as the preweanling rats (17
days old) received an acute injection of U-50,488 (5.0

mg/kg, s.c.) or amphetamine (2.5 mg/kg, i.p.).

Each day

a 60-min behavioral testing session began immediately
drug treatment.

Statistics.

To analyze the behavioral data,

repeated measure ANOVAs were performed across the five
days of conditioning, with a separate ANOVA performed

for the test day.

In order to assess whether

amphetamine produced behavioral sensitization a series

of t^tests (P<6.05) were performed to examine how the
saline- and amphetamine-conditioned rats responded to a
challenge dose of amphetamine.
Results

Conditioning: Effects of amphetamine on locomotor

activity.

Overall, rats receiving fepeated treatments
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with amphetamine had significantly more line-crosses

than saline controls on each day of conditioning (see
Figure 40) [Conditioning X Day interaction,

F(4,120)=95.34, P<0.001; and Tukey tests, P<0.05].
Amphetamine produced a progressive increase in locomotpr
activity across days (upper graph, Figure 40) [Tukey
tests, P<0.05 J.

Testing; Effects of U-50.488 challenge on loconiotor
activity in amphetamine-conditioned rats.

On the test

day, amphetamine-conditioned rats failed to display
sensitized locomotor activity following amphetamine
challenge (see triangles, right panel. Figure 40)

[i:( 14)=1.57, P>0.05].

Overall, rats challenged with U

50,488 had significantly more line-crosses than rats

challenged with amphetamine [test main effect, P(1,31)=
34.66, P<0.001].

On the test day, there were no

significant differences in line-crosses between

amphetamine- or saline-conditioned rats in response to
U-50,488 challenge.
Conditioning: Effects of amphetamine on stereotyped

sniffing.

Rats treated with amphetamine had

significantly more sniffing counts than saline controls

on each day of conditioning (see Figure 41)

[Conditioning X Day interaction, P(4,120)=3.89, P<0.05;
and Tukey tests, P<0.05].
Testing: Effects of U-50.488 challenge on
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stereotyped sniffing in amphetamine-conditioned rats.

On the test day, following amphetamine challenge,

saline-conditioned rats had significantly more sniffing
counts than amphetamine-conditioned rats (see triangles,

right panel. Figure 41) [t(14)=2.15, P<0.05].

Overall,

rats challenged with amphetamine on the test day had
significantly more stereotyped sniffing counts than rats

challenged with U-50,488 (see right panel. Figure 41)
[Condition X Test interaction, F(1,31)=4.26, P<0.05].
Conditioning; Effects of amphetamine on circling.

Amphetamine did not produce any circling during
conditioning (see Figure 42).
Testing: Effects of U-50.488 challenge on circling

in amphetamine-conditioned rats.

On the test day,

amphetamine challenge failed to produce any circling.
However, amphetamine-conditioned rats challenged with U
50,488 had significantly more circling counts than all

other groups (see right panel. Figure 42) [Conditioning
X Test interaction, F(1,31)=20.59, F<0.001; and Tukey
tests, P<0.05 J .
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FIGURE CAPTION

Figure 40.

Mean number of line-crosses of rats given

five daily injections of amphetamine (2.5 mg/kg, i.p.)

or saline starting at 11 days of age (n = 8).

At 17

days of age (i.e., after a 2-day interval), rats given
successive saline or amphetamine injections were then

given a single challenge injection of U-50,488 (5.0
mg/kg, s.c.) or amphetamine (2.5 mg/kg, i.p.).
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Figure 41.

Mean number of stereotyped sniffing counts

of rats given five daily injections of amphetamine (2.5
mg/kg, i.p.) or saline starting at 11 days of age {n =
8).

At 17 days of age (i.e., after a 2-day interval),

rats given successive saline or amphetamine injections

were then given a single challenge injection of U-50,488

(5.0 mg/kg, s.c.) or amphetamine (2.5 mg/kg, i.p.).
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Figure 42.

Mean number of circling counts of rats given

five daily injections of amphetamine (2.5 mg/kg, i.p.)
or saline starting at 11 days of age {n =8).

At 17

days of age (i.e., after a 2-day interval), rats given
successive saline or amphetamine injections were then

given a single challenge injection of U-50,488 (5.0
mg/kg, s.c.) or amphetamine (2.5 mg/kg, i.p.).
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Discussion

There was no evidence of crcss-sensitization

between U-50,488 and amphetamine.

Rats challenged with

U-50,488 showed a Similar increase in locomotor activity
regardless of whether they were conditioned with

amphetamine or saline.

Overall, these results suggest

that U-50,488 and amphetamine increase locomotor

actiyity by affecting different systems.
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General Discussion

The purpose of the present study was to examine U-

50,488's paradoxical effects on locomotor activity.

More Specifically, iri the adult rat U-50,488 decreases
locomotor activity; whereas, U-50,488 dramatically

increases the locomotor activity of the preweanling rat.
In these younger animalsj the increased locomotor
activity produced by. U-50,488 is similar to that

obseryed following DA agonist treatment.

Therefore, the

purpose of these experiments was to determine whether U50,488's locomotor activating effects are mediated

through a dopaminergic mechanism.

Six hypotheses were

originally proposed: (1) It was suggested that U-50,488

would decrease the locomotor activity of the 80-day-old
rat.

The results of Experiment Id supported this

hypothesis, as all doses (0.2—10.0 mg/kg) of U-50,488
reduced the locomotor activity of adult rats.

(2) As

predicted, U-50,488 increased the locomotor activity of
the preweanling rat (see Figures 2 and 7).

(3) It had

been originally hypothesized that U-50,488 would
potentiate amphetamine- and NPA-induced behaviors in
the preweanling rat.

However this was not

substantiated, as NPA actually attenuated U-50,488
induced locomotor activity (see Figure 7).
Amphetamine's actions were less clear, but the results
suggest that amphetamine also depresses the behaviors

165

of U-50,488 treated rats.

(4) Flupenthixol (a

nonselective DA receptor antagonist) was predicted to

reduce U-50,488-induCed locomotor activity.

The results

of Experiment 2 supported this hypothesis, as
flupenthixol produced a dose-dependent decline in U50,488-induced activity (see Figure 6).

(5) As

predicted, amphetamine and NPA stimulated regional Fos

expfession in the preweanling rat.

The areas showing

the greatest amphetamine- and NPA-induced Fos

immunoreactivity were the piriform cortex and cingulate
cortex (see Figures 11 and 16).

(6) In general, U

50,488-, amphetamine-- j and NPA-induced Fos
immunoreactivity did occur in the same brain regions.
However, instead of U-50,488 potentiating NPA- and

amphetamine-induced Fos, the DA agonists attenuated U-

50,488-induced Fos in the striatum and dlfactory
tubercles (see Figures 9 and 10).
The results of the present study showed that the

kappa opioid agonist U-50,488, the direct DA agonist

NPA, and the indirect DA agonist amphetamine, al1
independently enhanced behavioral responding in the
preweanling rat.

High doses of the DA antagonist

flupenthixol (0.4 and 0.8 mg/kg) reduced U-50,488
induced locomotor activity (see Figure 6).

This

suggests that U-50,488 may have been working via a

dopaminergic mechanism.

Subsequent experiments indicate
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howeverj that flupenthixol's ability to block U-50,488

induced locomotor activity may have been diie to a
general depression of motoric functioning and not due to
direct ihteractions with kappa neurons.

To better assess the kappa/DA interaction, U-

50,488-pretreated 17-day-bld rats were given amphetamine

or NPA prior to behavioral testing.

Although it was

predicted that U-50,488 pretreatment would potentiate DA

agonist-induced activity, acute treatment with
amphetamine had little or no effect on U-5Q,488-induced

behaviors.

Surprisingly, acute treatment with NPA

attenuated U-50,488-induced behavioral responding in the

17-day-old rat.

More specifically, U-50,488

dramatically enhanced locomotor activity, while NPA
reduced this activity in a dose-dependent manner.

These

findings were of particular interest because they

indicate that kappa opioid neurons and DA neurons
interact to modulate unleaTned activity in the

preweanling rat.

However, instead of the hypothesized

facilitafory mechanism, it appears that the kappa opioid
and DA systems have an antagonistic relationship.
Consistent with this, there was little evidence of

cross-sensitization between the kappa opioid agonist and
either of the D'^ agonists.

Specifically, U-50,488

challenge failed to elicit a cross-sensitized response
in amphetamine- or NPA—conditioned rats.
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One exception

was that rats receiving NPA or amphetamine during

conditioning displayed pronounced circlingfollowing U
50,488 treatment.

This was not true cross-sensitization

however, since the circling behavior did not show a
sensitized response after repeated amphetamine or NPA

treatment.

Importantly, regardless of conditioning

(i.e., NP'A or amphetamine), U-50,488 produced a dramatic

enhancement of locomotor activity oh the test day that
was similar to that of U-50,488 alone.

Chronic

pretreatment with NPA or amphetamine did not affect the

enhanced locomotor activity that was produced by a

challenge injection of U-50,488 (see right panel.
Figures 37 and 40).

These results are interesting,

because aCute treatment with NPA depressed U-50,488
induced locomotor activity in preweanling rats (see
Figure 35).

Overall, these results indicate that the

looomotor activaiting actions of U-50,488 may not be
mediated directly through a dopaminergic mechanism.

In addition to hehayiorai testing, thfeneuronal

response to amphetainine and Npa following U-50,488

pretreatment was examined by measuring the induction of
Fos, the protein product of the early response gene c
fos.

Presumably, increased Fos immunoreactivity is the

result of enhanced neurohal activity and, therefore, can

be used to identify those brain regions involved in the

mediation of behavior (Crawford et al., 1995; Graybiel
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et al., 1990; Sharp, Sagar, & Swanson, 1993).

Ip the

80-day-old rat, NPA reduce^ Fos expression in the
olfactory tubereles,

Conversely, NPA increased Fos

induction in the piriform cortex, an effect attenuated

by U-50,488 pretreatment.

In general, NPA's effects on

Fos expression are consistent with studies using the

direct DA agonist apombrphine, which increased F'os
immurioreactivity in the piriform cortex of the adult rat

(Wirtshafter & Asin, 1995; Wirtshafter, Asin, & Pitzer,
1994).

In the present study amphetamine reduced the

amount of Fos expression in the zonaincerta, while

having only trivial effects in all other brain regions^

The dose of amphetamine (2.5 mg/kg) used in Experiment
3c may be responsible for the lack of amphetamineinduced Fos expression.

A higher dose of amphetamine

(5.0 mg/kg) was shown to induce Fos expression in the
striatum and substantia nigra of the adult rat (Jaber et

al» , 1995).

With the exception of the habenula, U

50,488 alone did not enhance Fos expression in any of

the brain regions examined.

In general, this is

consistent with the existing adult literature (Crawford
et al., 1995).

in the preweanling rat, U-50,488, as well as

amphetamine and NPA, produced Fos immunoreactivity.

U-50,488 enhanced Fos expression in the striatum,

olfactory tubercles, pirifprm cortex, habenula, preoptic
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area, amygdala, stria medullaris, cingulate cortex, and
septal area of the 17-day-old rat.

Of special interest

was the striatum, as U-SO,488-induced locomotor activity

was accompanied by dramaticaily increased Fos expression
in the striatum.

NPA treatment blocked both U-50,488

induced Ipcdmotion and striatal FOs expression.

Thus

suggesting that the striatum may be one of the brain
regions mediating U-50,488's locomotor activating
effects.

The DA agonists also affected Fos

immunoreactivity in other brain regions of the

preweanling rat.

For example, amphetamine depressed U-

50,488-induced Fos expression in the olfactory

tubercles; whereas, amphetamine and NPA enhanced Fos
expression in the piriform cortex.

These results

indicate that while DA agonists can independently
affect Fos immunoreactivity, these same DA agonists will

modulate U-50,488-induced Fos expression in a number of
brain regions.

Evidence suggests that kappa bpioids have dual

opposing effects on activity: a motor activating effect
mediated by non-dopaminergic pars reticulata cells and a

motor inhibitory effect mediated through the pars
compacta DA cells (Matsumoto et al., 1988; Thompson &

Walker, 1990).

Redeptor binding studies have indicated

that large amounts of kappa opiate receptors are present
in the striatum and pars compacta of the substantia
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nigra, with low levels present in the pars retiGulata
(Matsumoto et al., 1988; Merchenthaler et al., 1986).

Similarly, binding studies have found high levels of DA
receptors in the striatum and pars compacta of the

substantia nigra, with low level of DA reeeptors in the
pars reticulata (Kreiss et al., 1995; Porter, Greene,
HigginS, & Greenamyre, 1994; Spampinatb, Gozlan, Daval,
Fattaccini, & Hamoii, 1988).

Therefore, based on these binding studies it is

possible that the striatum is the brain region
responsible for the present behavioral data.

More

speeifically, it is possible that actiVation of the

kappa opioid reoeptprs in the pars compacta inhibits DA
neurons projecting from the substantia nigra to the

striatum.

If true, this would account for U-50,488's

ability to depress NPA-induced sniffing.

Unfortunately,

this does not account for NPA's ability to depress U50,488^induced activity;

At present there is no

adequate explanation for this effeet.

In general,

however, activation of kappa opioid receptors in the
adult rat is associated with a reduction of DA-mediated

behavior (Crawford et al., 1995; Di Chiara & Imperato,

1988; Matsumoto et al., 1988).

Therefore, a similar

antagonistic relationship between the kappa opioid and
DA systems in the preweanling rat is not surprising.
In the cross-sensitization experiments, chronic
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treatment with amphetamine or NPA did not affect U50,4S8-inducedldcomotor activity (see Figures 37 and

40).

However, U-50,488 Challenge did produce circling

in amphetamine- and NPA-conditionedpreweanling rats
(see Figures 39 and 42).

Importantly, circling only

occurred in rats that had received both U-50,488 and one

of the DA agonists.

Apparently circling is a kappa

opioid mediated effect, but it is only expressed after
prior treatment with NPA or amphetamine.

Thus it is

possible that normal dopaminergic functioning may mask

circling, but that the heurobiological changes produced
by chronic DA agonist treatment (i.e., changes in
receptor numbers, G-proteins, receptor sensitivity)

allowed U-50,488-induced circling to be expressed.
Curiously, bilateral microinjections of amphetamine or

apomorphine into the substantia higra Causes circling in
rats (JeTussi & Click, 1976).

So it is possible that U

50,488 and the DA agonists combine to produce circling

behavior by activating this brain region.

Consistent

with this, the substantia nigra is known to have an

abundance of both kappa opioid and DA Di and D2

receptOTs (Kreiss et al., 1995; Matsumoto et al., 1986).
It had been originally hypothesized that the

interaction between the kappa opioid and DA systems in
the preweanling rat was of a facilitatory nature: That
is, it was predicted that U-50,488 would potentiate DA
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agonist-induced locomotor activity.

Instead, these

systems seem to interact in an antagonistic fashion in
the preweanling rat.

Thus, this still leaves the basic

question of why U-50,488 paradoxically increases the

locomotor activity of the preweanling rat, while leaving
the activity of the adult rat unaffected.

Although the

DA system appears to be eliminated as a possible

explanation, it is conceivable that ontogenetic changes

in NMDA receptors may be responsible for U-50,488's
actions.

Dizocilpine, an NMDA receptor antagonist, produces
a robust increase in locomotor activity in the

preweanling rat (Duke, BQlanbs, Garmsen, Clair, &
McDougail, 1995; Scalzo & Burge, 1994).

Evidence for a

kappa/NMDA interaction includes: receptor binding

studies showing that high levels of NMDA receptors are
located in the striatum and substantia nigra of the rat

(Carroll, Holloway, Brotchie, & Mitchell, 1995; Snell &

Johnson,,1985).

Second, dizociIpine, 1ike U-50,488,

increases Fos expression in the striatum (Liu,
Nickolenko, & Sharp, 1994).

And fina1ly, dizoci1pine

produces no cross-sehsitization in rats conditioned with
amphetamine or NPA-

Thus, dizocilpine's locomotor

activating effects, like U-50,488's, do not appear to be

mediated thfou^h a dopaminer^

mechanism.

Once again,

U-50,488 and dizocilpine share the common feature that
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they both dramatically increase the locomotor activity
of preweanling rats well above that seen in adults.

Therefore, although speculative, it is possible that U
50,488 and dizocilplne work through common mechanisms
independent of actions on DA neurons.

In summary, the kappa opioid agonist, U-50,488,
dramatically increases the locomotor activity of the
preweanling rat.

The striatum may be involved in the

mediation of this activity, as enhanced striatal Fos
expression accompanied the U-50,488-induced increase in
locomotor activity.

Importantly, the direct DA agonist

NPA attenuated Fos expression in the striatum, as well

as producing a dose-dependent decrease in U-50,488's
locomotor activating effects.

The opposite was also the

case, NPA-induced sniffing was attenuated by U-50,488.
when considered together, these results indicate that

the DA and kappa systems have a generally antagonistic
relationship with each other.

The lack of cross-

sensitization between U-50,488 and amphetamine or NPA

provides further evidence indicating that U-50,488's
locomotor activating effects are not mediated directly
through a dopaminergic mechanism.

One possibility is

that U-50,488's locomotor activating effects may be
meditated through a non-dopaminergic mechanism in the
striatum.
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